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Abstract 
Age-like Phenotype of Microglia During HIV-1 Infection 
Natalie Cheng Chen 
Julio Martin-Garcia    Supervisor, Ph.D. 
 
 
 
 
HIV Associated Neurocognitive Disorder (HAND) persists in 50% of infected 
patients despite treatments. Moreover, HAND potentiates aging-associated 
neurocognitive decline as the infected population grow older. Microglia cells support 
productive HIV-1 infection in the brain and elevated senescence markers including p53 
and p21 have been detected in microglia in HAND tissues. We hypothesize that HIV-1 
induces age-like phenotypes in microglia. In an in vitro model of primary human 
microglia infected with HIV-1 pseudotype, we examined various markers of aging 
including the expression of cell cycle inhibitors (p53, p21 and p16), DNA damage 
associated p53 binding protein 1 (53BP1) foci formation, senescence associated β-
galactosidase (SA-β-gal) activity, and the development of Senescence Associated 
Secretory Phenotype (SASP). Finally, we examined mitochondrial reactive oxygen 
species (ROS) and mitochondrial respiration, which are known to be altered during 
organismal aging. We detected elevated expression of p53 and p21, increased 
percentage of cells expressing 53BP1 foci and β-gal, as well as significantly elevated 
levels of various cytokines including IL8 and IL6 post infection. The development of age-
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like phenotype is accompanied by increased mitochondrial ROS production and altered 
mitochondrial respiratory activity. Finally, exposure to the supernatant of infected 
microglia results in elevated p21 and caveolin-1 protein expression. Overall, we have 
demonstrated for the first time age-like phenotypes in human microglia during HIV-1 
infection. HIV-1 induced microglial age-like phenotype could play a role in the 
development of HAND. 
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Chapter 1: Introduction 
 
1.1 General Background 
 With the advent of combination anti-retroviral therapy (cART), which for most 
treated patients effectively controls HIV-1 viral replication, the proportion of patients 
developing HIV-1-associated dementia (HAD) has declined dramatically. However, 
recent population-based studies suggest that around 50% of all infected patients 
continue to develop HIV-1-associated neurocognitive disorders (HAND) to varying 
degrees (Chan and Brew 2014; Heaton et al. 2011; Nightingale et al. 2014; Sacktor et al. 
2016). Remarkably, patients with even the mildest form of HAND -- asymptomatic 
neurocognitive impairments (ANI) -- have much higher chances of displaying impairment 
with daily activities due to cognitive decline as they age, compared to non-infected age-
matched controls. This suggests that ANI potentiates age-associated cognitive 
impairment and having ANI is predictive of more serious impairment later on (Grant et al. 
2014). Currently there are no effective treatments designed specifically for HAND and 
patients are managed with regimens commonly prescribed for patients with aging-
related dementia such as antioxidants, N-methyl-D-aspartate (NMDA) antagonists and 
life style adjustments, such as exercising. More efforts are required to elucidate the 
molecular mechanisms underlying the development of HAND in order to design targeted 
therapies that could more effectively ameliorate the neurocognitive impairments.  
 Together with macrophages, microglia are the major cell type productively 
infected by HIV-1 in the CNS, and therefore it is also likely a major contributor to 
neurotoxicity observed during chronic HIV-1 infection (Gonzalez-Scarano and Martin-
Garcia 2005). Various groups have proposed that the pro-inflammatory sequelae of 
microglia activation during HIV-1 infection, including altered cytokine secretion, comprise 
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a major tenant of HAND development (Gonzalez-Scarano and Martin-Garcia 2005; Lull 
and Block 2010). Advanced technology and dedicated efforts heralded significant 
advancement in our understanding of microglia physiology including unique molecular 
programs during microglial activation and aging, which could add new meanings to the 
implication of HIV-1 infected microglia during HAND.  
 The objective of the present review is to critically assess functional changes of 
microglia during chronic HIV-1 infection taking into consideration the aging 
demographics of the HIV-1-infected population, in order to identify molecular pathways 
that could serve as potential therapeutic targets.  
1.2 Microglia Origin and Function  
 Introduced as the non-astroglial, non-neuronal “third element” of the CNS, 
microglia were first characterized in the 1930’s by del Rio Hortega using silver staining 
technique (Rio-Hortega 1939). It was noted that microglial cells have the capacity to 
migrate, proliferate and phagocytose. Since then, advanced staining techniques and 
genetics-based studies elucidated that microglia belong to the myeloid 
phagocytic/monocytic lineage (Murabe and Sano 1982; Perry et al. 1985; Smith et al. 
2013). Unlike other tissue resident macrophages, which are hematopoietically derived, 
the majority of microglia at steady state originate from a self-renewing cohort of yolk sac-
derived erythro-myeloid progenitors (Ginhoux et al. 2013; Gomez Perdiguero et al. 2015; 
Sheng et al. 2015). Although there are significant variations in microglia density (0.5%-
16.6%) and morphology depending on brain regions, whether region-dependent 
heterogeneity in microglia function exists remains largely unknown (Mittelbronn et al. 
2001; Olah et al. 2011). Recent murine studies demonstrate differential genetic profiles 
depending on the brain regions, suggesting region-dependent functional differences 
(Grabert et al. 2016). At the basal level, microglia act as sentinels to survey the 
environment of the CNS through their motile processes and dynamic contacts with 
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neural cells, including astrocytes and neurons (Kettenmann et al. 2011). Recent 
evidence suggest that microglia prune pre-synaptic axons and post-synaptic dendritic 
spines to fine-tune synapses (Kettenmann et al. 2013; Tremblay et al. 2010). During 
neuronal development and maturation, a period of significant cell turnover, microglia also 
contribute to the clearance of dead cell debris through phagocytosis (Michell-Robinson 
et al. 2015). In the context of neurodegenerative diseases, microglial cells play essential 
roles in the clearance of beta amyloid (Aβ) proteins (Liu et al. 2010), the accumulation of 
which correlates significantly with neurocognitive impairments. Microglia express 
receptors for various neurotransmitters, cytokines as well as sensors for innate immunity 
including pattern recognition receptors such as Toll-like receptors (TLR) (Neumann and 
Wekerle 2013). Upon exposure to activating stimuli such as invading pathogens, 
microglial cells quickly mobilize to the site of insult and mount an innate immune 
response, and may help establish adaptive immunes responses, through phagocytosis, 
secretion of cytokines and chemokines, and antigen presentation (Aloisi 2001; Pascual 
et al. 2012; Shrikant and Benveniste 1996; Smith et al. 2010; Wraith and Nicholson 
2012). Whether microglia activation is neurotoxic or neurotrophic is highly context-
dependent. For instance, “acutely activated” (24 h treatment with the TLR4 ligand 
lipopolysaccharide [LPS]) microglia release pro-inflammatory cytokines and contribute to 
reduced neuronal survival rate, whereas “chronic activation” (72 h LPS exposure) of 
microglia induces secretion of anti-inflammatory cytokines and development of a 
neuroprotective phenotype (Cacci et al. 2008). As a result, the nature, duration and 
strength of microglial response to foreign insults are tightly regulated by inputs from both 
neural cells and components of the immune system. For example, depending on the 
type of stimuli, microglia could assume a pro-inflammatory/antigen-presenting activation 
state or anti-inflammatory/tissue-repairing activation state, similar to the M1 and M2 
phenotypes traditionally used to describe macrophages, as demonstrated predominantly 
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with murine models (Ponomarev 2011) (Table 1). Evidence obtained with primary human 
cells suggests, however, that microglia initiate slightly different activation programs 
compared to that of monocyte-derived macrophages (MDMs). When stimulated with M1-
polarizing agents such as interferon (IFN)γ, human adult and fetal microglia and MDMs 
all express elevated levels of CD80 and CCR7 with fetal microglia exhibiting the least 
elevation in CD80 and CCR7. On the other hand, treatment with M2 polarizing agents 
such as interleukin (IL)-4 leads to significantly increased CD23, CD163, CD206 and 
CD209 in MDMs, CD209 in adult microglia and CD209 and CD206 in fetal microglia 
(Durafourt et al. 2012). The different activation patterns between microglia and MDMs is 
just one of many functional characteristics that differentiate microglia from macrophages. 
For instance, adult microglia express qualitatively similar but quantitatively lower levels 
of antigenic markers including CD45, CD11b, HLA-DR, CD14, CD200R, CD16, CD32, 
CD64, CD86, CD163, CD68, CD4 and Ionized calcium-binding protein-1 (Iba-1) 
compared to macrophages (Kettenmann et al. 2011; Melief et al. 2012). Gene profiling 
and quantitative mass spectrometry analysis of murine cells demonstrate that microglia 
uniquely and highly express a group of transforming growth factor β (TGF-β)-dependent 
molecular signatures compared to other neuronal and immune cells, including resident 
macrophages in peripheral tissues (Butovsky et al. 2014). To conclude, microglia are an 
important and unique class of CNS-resident cells that perform various immune-
modulatory functions to insure neuronal integrity. Disturbed microglial function has been 
attributed to the development of various neurological disorders including Alzheimer’s, 
Huntington’s, and Parkinson’s, as well as HAND (Block et al. 2007; Nakajima et al. 
2007).  
1.3 Age-Dependent Changes in Microglial Function – Activation and Senescence 
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 Microglial function evolves during the course of an individual’s lifespan (Figure 1). 
Immuno-histochemical staining of brain sections of pre-term fetuses detected the 
presence of microglial cells in human CNS as early as 9 gestational weeks, which 
precedes birth and onset of hematopoiesis in the human bone marrow and liver (Verney 
et al. 2010). This observation is consistent with the discovery that the majority of adult 
microglia derive from embryonic progenitors, rather than from circulating monocytes 
generated during post-natal hematopoiesis. Fetal microglia strikingly differ from their 
mature, adult counterparts. In early gestational weeks, microglia appear amoeboid 
resembling activated microglia morphology and go through gradual ramification with 
increasing gestational age. Phenotypic analysis demonstrate that fetal microglia at pre-
myelinating 16-20 weeks of gestational age express CD4, CCR5, CD11b, CD11c, CD14, 
CD45, CD68, CD86 and human leukocyte antigen-D-related (HLA-DR), and the staining 
intensity of antigenic markers weakens with increasing gestational age (Esiri et al. 1991; 
Rezaie and Male 1999; Wang et al. 2002). These observations suggest that fetal 
microglia have a partially activated state, which diminishes with maturation.  
 At the other end of the age spectrum, microglia also exhibit elevated activation 
status. Positron emission tomography (PET) demonstrated increased R-[11C] PK11195 
ligand binding, suggesting elevated microglial activation, in healthy aged humans 
(Schuitemaker et al. 2012). Additionally, molecular markers associated with microglia 
activation including major histocompatibility complex II (MHC II), CD11b and Iba1 have 
been shown to be elevated in microglia in tissues of aged individuals without overt 
neurocognitive deficits (Frank et al. 2006; Rogers et al. 1988; Ziv et al. 2006). The 
potential consequences of such chronically elevated activation of microglia during aging 
have garnered significant scientific interest in recent years, since the “microglial 
dysfunction hypothesis” suggests that age-related alteration of microglial function 
contributes to the onset of various neurodegenerative diseases (Wong 2013). 
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Another very important aspect of the age-associated alterations in microglia 
function is the development of the microglial senescence program. The concept of 
cellular senescence was first introduced by Hayflick and Moorhead to describe the 
limited lifespan of primary human cells in vitro, and has since been observed to play 
important roles in regulating human tissue aging and aging-related pathology (Hayflick 
and Moorhead 1961). It has been proposed that senescence is beneficial to reproductive 
fitness early in life through fine-tuning organ development during embryogenesis and as 
an anti-tumor mechanism by inducing permanent cell cycle arrest of neoplastic cells 
(Childs et al. 2014). As an organism ages, however, senescence appears to have 
detrimental health effects and contributes to the progressive loss of tissue and organ 
function during aging. More specifically, senescent phenotypes have been observed in 
various cell types residing in different tissues including bronchial cells, adipocytes and 
pancreatic β cells, as well as in astrocytes, and development of senescence in those 
cells has been shown to contribute to and/or to be associated with the onset of 
pulmonary fibrosis, obesity, type 2 diabetes and Alzheimer’s disease, respectively (Bhat 
et al. 2012; Chesnokova et al. 2009; Chinta et al. 2013; Minagawa et al. 2011; Minamino 
et al. 2009; Sone and Kagawa 2005). Although it still remains to be clarified whether 
cellular senescence directly promotes aging, eliminating senescent cells appears to 
prolong the health span of both BubR1-hypomorphic progeroid and normal mice (Baker 
et al. 2016; Baker et al. 2011), and 'senolytic' drugs that can selectively kill senescent 
cells may potentially have remarkable beneficial effects in terms of health span and/or 
life span (Chang et al. 2016; Zhu et al. 2015a; Zhu et al. 2015b). It has been proposed 
that neutralization of detrimental effects of senescent cells or elimination of senescent 
cells could prevent the onset of various aging-related diseases, including 
neurodegenerative diseases (Salminen et al. 2011). As a result, much effort has been 
spent on characterizing senescence in various cell types in vivo and in vitro. Senescent 
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cells in vitro have many distinguishing characteristics including elevated expression of 
p53-p21 axis and/or p16Ink4a pathway that ultimately prevent entry into the S phase of the 
cell cycle; permanent DNA damage foci with accumulation of the p53-binding protein 
53BP1 and/or the topologically-changed histone γH2Ax; increased enzymatic activity of 
the lysosomal hydrolase senescence-associated β-galactosidase (SA-β-Gal); and the 
development of the so-called senescence-associated secretory phenotype (SASP), 
which is a distinct secretory profile consisting of various pro-inflammatory cytokines, 
chemokines and metalloproteinases (Munoz-Espin and Serrano 2014) (Table 1). It was 
also shown that the onset of SASP is dependent on the initiation of DNA damage 
response and not present in all senescent cells (Rodier et al. 2009). The aforementioned 
traits need to be used in combination to characterize the senescent phenotype since any 
individual characteristic can be found independent of the initiation of the cellular 
senescence program. Cell culture experiments demonstrate that microglia undergo 
telomere shortening, which is a classic inducer as well as characteristic of senescence 
(Flanary and Streit 2004). Additionally, emerging evidence suggest that microglia could 
potentially develop a senescence-like phenotype with in vitro passaging. Compared to 2 
days in vitro (DIV) microglia, 16 DIV murine microglia demonstrate elevated SA-β-Gal 
positivity, which might suggest the onset of cellular senescence (Caldeira et al. 2014). 
Importantly, transition to a potentially senescent phenotype correlated with reduced 
phagocytic and migratory capacities, indicating that what the authors describe as an 
“age-like phenotype” in microglia could result in impairment of its normal functions 
(Caldeira et al. 2014). However, it seems striking that the establishment of senescence 
may occur in microglia after a relatively short time of in vitro culture. In addition, the 
observation of reduced phagocytosis and mobility in these cells is not in agreement with 
very recent evidence obtained from aging mice using high spatial-resolution electron 
microscopy, which describes more active microglia in 14-month old than in 3-month old 
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mice. Imaging captured increased instances of microglia extending their processes to 
encircle neuronal synapses including pre-synaptic axon terminals and post-synaptic 
dendritic branches, which, together with the shrunken appearances of and empty spaces 
surrounding these neuronal processes, suggests active digestion of neuronal synapses 
by microglia in the aging mice (Bisht et al. 2016). These discrepancies could be due to 
the fact that microglia exhibit differential rates of phagocytosis depending on the objects 
being ingested – the in vitro study used beads for phagocytosis assay while the in vivo 
experiment observed microglial synaptic pruning, which is a more physiologically-
relevant model. In addition, it is possible that sub-populations of microglia may exist in 
the aged brain, and that some may exhibit a phenotype more similar to that described in 
vitro. Although microglial senescence has not been examined systematically in human 
tissues, analysis of aged human brain tissues revealed the presence of dystrophic 
microglia, characterized as having altered cytoplasmic structures including de-ramified, 
tortuous processes with spheroidal bulbous swellings, which often progresses to 
fragmented cytoplasm (Streit et al. 2004). This dystrophic microglia phenotype is 
observed to increase with aging and has been detected in neuropathological conditions 
including Alzheimer’s disease (AD) (Yang et al. 1998). Thus, the cumulative evidence 
suggests that aging is a significant modifier of microglial function. Although the 
progression and exact nature of microglial “aging” remains to be clarified, activation and 
senescence appear to be integral processes of the microglial “aging program”.  
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Figure 1. Age-dependent Changes in Microglia Microglia exhibit phenotypic changes 
over an individual's lifetime. During fetal development, microglia express activation 
markers including HLA-DR, CD11b and CD68, indicating an activation state (denoted by 
blue) that seems to be needed to accomplish proper differentiation and development, 
and clearing of dead cells. This activation state decreases with maturation and usually 
leads to a healthy, homeostatic status that predominates until later in life, when a build-
up of chronic, persistent activation may occur. In this context, chronic activation may 
result in deleterious changes that associate with dysfunctional microglia (transition from 
blue to grey), characterized by morphological changes such as condensed chromatin 
and fragmented cytoplasm, and functional changes such as increased synaptic pruning 
that contributes to loss of neuronal synapses. This dysfunctional state may be reflective 
of a senescence phenotype and could contribute to the development of 
neurodegenerative diseases. 
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1.4 HIV-1 Infection and Viral Life Cycle 
Since the first reported case of AIDS  in 1981, much has been accomplished in 
characterizing the molecular and cellular mechanisms of HIV-1 infection, replication and 
pathogenesis in the past three decades (Barre-Sinoussi et al. 1983; Gottlieb et al. 1981). 
HIV-1 is an enveloped virus that contains two copies of single stranded RNA encased in 
capsid proteins. The HIV-1 viral genome encodes for nine structural and accessory 
proteins that play important roles in facilitating viral life cycle including env, gag, pol, tat, 
rev, nef, vpr, vif and vpu(Lu et al. 2011). In order to enter host cells, the envelope region 
of the virus first binds to the cell surface molecule CD4, which is the main receptor for 
HIV-1(Dalgleish et al. 1984; Maddon et al. 1986). Following binding with CD4, the 
envelope protein undergoes conformational changes, allowing subsequent interactions 
of the envelope with co-receptors including CXCR4 and CCR5, which are critical for the 
entry of X4 and R5 tropic viruses respectively(Feng et al. 1996). In fact, individuals 
deficient in co-receptor expression are protected from HIV-1 infection(Liu et al. 1996). 
Following receptor binding, the viral envelope or the lipid bilayer on the exterior of the 
viral particle fuses with the cell membrane and the viral capsid is delivered into the 
cytoplasm, where it uncoats to release the viral RNA and proteins. Positive sense viral 
RNA is reverse transcribed into DNA, which is then translocated into the nucleus in the 
pre-integration complex (PIC). In the nucleus, the viral DNA is integrated into the host 
genome and hijacks the host cellular machinery to transcribe and translate its own 
genome to form new viral RNA and viral proteins, which are then assembled into mature 
viruses to be released from the infected host cells. The released virion can then infect 
other cells(Nisole and Saib 2004). Our knowledge of HIV-1 viral replication has enable 
the discoveries and developments of successful antiviral treatments, which have 
transformed HIV-1 infection from a fatal disease in the early days of its discovery to now 
a manageable chronic disease. Most patients who are on effective treatments can have 
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a normal life expectancy(Barre-Sinoussi et al. 2013). Unfortunately, persistent immune-
activation associated with viral infection and side effects of chronic treatments can result 
in various debilitating end organ diseases including neurological disorders. HIV 
associated neurocognitive impairments (HAND) can be diagnosed based on a battery of 
cognitive tests and categorized into asymptomatic neurocognitive impairment (ANI), mild 
neurocognitive disorder (MND) and HIV associated dementia (HAD) in increasing order 
of severity. Although the prevalence of HAD has significantly declined with effective 
treatments, around 50% of patients continue to develop the milder forms of HAND 
depending on the study. The neurocognitive complications of chronic HIV-1 infection 
remain a significantly public health problem in the post cART era(McArthur et al. 1993).  
1.5 Persistent Viral Presence During cART Era  
Despite stable courses of cART that may result in undetectable levels of virus in 
blood, HIV-1 persists in most infected patients and it is possible that the CNS may be 
one anatomical reservoir where the virus resides. Microglia constitute the only resident 
cells in the human brain parenchyma that can support productive HIV-1 infection and 
could thus serve as one of the potential cellular reservoirs within the CNS during chronic 
HIV-1 infection. This is supported by evidence demonstrating significant cerebrospinal 
fluid (CSF) viral escape in some patients on effective cART that have low or 
undetectable plasma HIV-1 RNA levels. In a retrospective analysis that examined viral 
load in patients’ CSF and plasma, Eden et al. detected a median viral load of 121 HIV-1 
RNA copies/ml in the CSF of 7 patients out of a total of 69 patients analyzed, all of 
whom had undetectable plasma viral load by standard assays (below 50 copies/ml) and 
were asymptomatic for neurocognitive diseases (Eden et al. 2010). In two additional 
retrospective studies that selected for patients who had developed neurocognitive 
deficits and brain magnetic resonance imaging (MRI) abnormalities, CSF viral escape 
(median viral loads of 880 and 3900 copies/ml, respectively) was detected in all patients 
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with undetectable plasma viral load (Canestri et al. 2010; Peluso et al. 2012). 
Furthermore, phylogenetic analyses have revealed compartmentalization of HIV-1 in the 
CSF compared to peripheral blood early post-infection, which suggests that HIV-1 
evolves very quickly to adapt to the CNS microenvironment early on (Schnell et al. 2010; 
Sturdevant et al. 2012). This is in addition to the well-established compartmentalization 
of viral strains between brain and blood or lymphoid tissues determined with autopsy 
samples derived from patients with neurocognitive manifestations associated with HIV-1 
infection (Gonzalez-Scarano and Martin-Garcia 2005). Furthermore, genetic and 
functional studies of the envelope gene of viral strains isolated from brain, and the 
comparison with those from blood or lymphoid tissues of the same infected patients, 
have demonstrated genetic changes that contribute to a reduced dependence on the 
primary receptor for infection, namely CD4; this reduced CD4 dependence confers these 
strains an increased ability to infect cells with low CD4 expression, compared to that of 
CD4+ T cells, such as microglia and macrophages (Gonzalez-Scarano and Martin-
Garcia 2005; Martin-Garcia et al. 2006; Martin-Garcia et al. 2005; Rossi et al. 2008). The 
importance of macrophages and microglia during HIV-1 infection is further emphasized 
in a model of simian immunodeficiency virus (SIV)-infected rhesus macaques with 
depletion of CD4+ T cells, in which infection is sustained by macrophages and microglial 
cells (Micci et al. 2014). The above evidence suggests that HIV-1 has evolved to reside 
in long-lived cells such as microglia within the CNS, to achieve certain levels of viral 
replication refractory to immune pressure and antiretroviral therapies that, in most 
patients, effectively restrict viral load in the peripheral blood. 
The presence of HIV-1 viral reservoir in the CNS is bolstered by the detection of 
stable SIV viral DNA in infected macaques even when viral RNA in circulation decreases 
to an undetectable level, suggesting a state of viral latency (Clements et al. 2011; 
Clements et al. 2005; Zink et al. 2010). Isolated microglia from SIV-infected animals and 
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HIV-1-infected human brains start to produce infectious virus upon in vitro culture, which 
further validate the observation that microglia harbor infectious HIV-1 virions (Brinkmann 
et al. 1993; Ghorpade et al. 2005). Overall, ex vivo and in vitro evidence suggest that the 
CNS, and microglial cells in particular, can potentially serve as one of the anatomical 
and cellular reservoirs, respectively, where HIV-1 may persist during chronic infection 
despite successful cART. As a result, it is important to better understand the interaction 
between HIV-1 and microglia during chronic HIV-1 infection. 
1.6 The Effect of HIV-1 Infection on Microglial Function 
1.6.1 Microglia activation during HIV-1 infection 
Abundant clinical evidence suggests a state of immune activation in the CNS of 
patients infected with HIV-1(Table 1). Brain imaging of HIV-1-infected patients on cART 
using positron emission tomography imaging and 11C-PK11195 as an in vivo marker of 
microglia activation, reveals activation of microglia even in the absence of neurological 
symptoms (Garvey et al. 2013). In vivo and ex vivo studies of HIV+ patients demonstrate 
that increased immune activation in the CNS of infected patients compared to uninfected 
controls could be attributed to infected microglia (Andersson et al. 1998). 
Immunocytochemistry staining of brain sections from HIV-1-infected patients indicates 
that, compared to tissues from uninfected controls, there are significant increases in 
MHC class II, CD163, IL-1 and tumor necrosis factor (TNF)α levels, indicative of immune 
activation. The CSF from HIV+ patients also contains increased levels of TNFα, β2-
microglobulin and neopterin, which are also markers of macrophage activation (Tyor et 
al. 1992). IL-1α was elevated in microglial cells derived from brains obtained from HIV-1-
infected patients, and S100β, a cytokine that induces intraneuronal calcium levels, was 
also found to be elevated in the CNS of HIV-1-infected patients, which could contribute 
to neuronal degeneration (Stanley et al. 1994). Combined reverse 
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transcriptase/polymerase chain reaction, in situ hybridization and immunohistochemistry 
in brain and spinal cord sections of patients infected with HIV-1 demonstrate that cells of 
the macrophage lineage, including microglia, are positive for TNFα mRNA and therefore 
represent possible sources of TNFα in the brain during HIV-1 infection (Wesselingh et al. 
1997). This was in contrast with the results of an ex vivo study utilizing microglia isolated 
from brain tissues of patients who were HIV seropositive. The cells were confirmed to be 
CD68+ and to express p24 antigen by immunofluorescence and were subsequently 
stimulated with LPS for 24 h. Surprisingly, HIV-1-infected microglia secreted lower levels 
of TNFα both in basal conditions and post-LPS challenge than control microglia, 
suggesting that microglia chronically infected by HIV-1 may exhibit subdued pro-
inflammatory profile compared to uninfected cells, despite the fact that most of the 
microglia stain positive for HLA-DR, indicative of activation (Ghorpade et al. 2005). 
Unfortunately, a more extensive secretory profile was not investigated to fully examine 
the activation status of infected microglia in this particular study. 
Immunohistochemistry staining of brain sections from chronically-infected 
patients who have developed HIV-1 encephalitis (HIVE) revealed elevated levels of IL-1 
and caspase-1 in microglia, which suggests that inflammasome activation, as a part of 
the microglia activation program, could contribute to the development of HAND (Zhao et 
al. 2001). This was confirmed in an in vitro study in which HIV-1 infection resulted in 
inflammasome activation, as indicated by the release of IL-1β and caspase-1 activation 
(Walsh et al. 2014). Using an in vitro primary human microglia model, HIV-1 infection 
results in secretion of IL-8, IL-6, monocyte chemotactic protein 1 (MCP-1), TNFα and 
RANTES (or “regulated on activation, normal T cell expressed and secreted”), in a 
Beclin-1-dependent manner (El-Hage et al. 2015). Microglial activation is also observed 
in animal models of HIV-1 infection of the CNS. In brain tissues of rhesus macaque 
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monkeys infected with SIV, in situ hybridization showed that a majority of infected 
microglia expressed MHC class II, indicating glial activation (Brinkmann et al. 1993). 
Astroglial activation, as indicated by microglial nodule formation and increased IL-1β and 
IL-6 expression, was also observed in severe combined immunodeficiency (SCID) mice 
that developed encephalitis upon receiving xenografts of HIV-1-infected cells (Persidsky 
et al. 1996). Although most of the evidence suggest that microglial cells predominantly 
exhibit pro-inflammatory status in the context of HIV-1 infection, surface marker analysis 
on brain sections from patients with HIVE detected elevated levels of CD163 in 
association with ramified microglia, suggesting a de-activated or alternatively-activated 
phenotype (Roberts et al. 2004). 
All evidence considered, it is likely that microglia exist in a spectrum of activation 
status in the context HIV-1 infection, however the mechanisms regulating differential 
microglial activation during the course of HIV-1 infection remain largely unknown. Pro-
inflammatory profiles seen in microglia during HIV-1 infection could be due to multiple 
factors including infection itself, viral protein-mediated or caused by cytokine secretion, 
possibilities which can be further explored in an in vivo setting. Using a primary human 
fetal microglia model, it was shown that HIV-1 integrase inhibitor Raltegravir significantly 
reduced the levels of multiple cytokines including IL-8, IL-10, TNFα and IL-6, which 
suggest that the infection definitely plays an important role in either the initiation or 
propagation of the pro-inflammatory phenotype (Tatro et al. 2014). 
1.6.2 HIV-1 infection affects the apoptosis vs. survival pathway of microglia 
HIV -1 infection also affects the balance of microglial survival and death. Recent 
evidence suggests that terminally differentiated tissue macrophages have the potential 
to proliferate in order to self-maintain under favorable conditions (Hashimoto et al. 
2013)(table1). The intricate balance of this process is perturbed during HIV-1 infection, 
	  	  
16	  
since it was shown to inhibit granulocyte-macrophage colony-stimulating factor (GM-
CSF)-mediated CD68+ macrophage/microglia proliferation observed in vitro as well as in 
brain tissues using Ki67 and BrdU (5-bromo-2'-deoxyuridine) staining (Cosenza-Nashat 
et al. 2007). In vivo and in vitro evidence also suggest that productive HIV-1 infection 
promotes a pro-apoptotic environment by up-regulating BCL2-associated X protein (Bax) 
(pro-apoptotic) and inactivating B-cell lymphoma (Bcl)-2 and Bcl-x (anti-apoptotic) 
(Krajewski et al. 1997). However, it is unclear whether microglial apoptosis occurs, and 
how widespread it is, during HIV-1 infection. On the other hand, there have been also 
studies demonstrating that microglial cells avoid HIV-1 infection-mediated cell death 
through up-regulation of pro-survival pathways. For instance, primary human microglia 
promote cell survival by up-regulating BCL2 Associated Athanogene (BAG) 3, whose 
down-modulation seems to be required for caspase-3-mediated apoptosis following 
infection (Rosati et al. 2009). Other studies suggest that HIV-1 infection could modulate 
cell survival at the level of cell cycle regulation. For example, an aberrant profile of cell 
cycle regulators was observed using the SIV model. In brain tissues with SIV 
encephalitis, levels of E2F1 and retinoblastoma susceptibility gene product (pRB) were 
shown to be elevated in neurons and glial cells in both frontal cortex and basal ganglia 
using immunofluorescence staining (Jordan-Sciutto et al. 2000). E2F and pRB are 
required for the initiation of S phase during cell cycle progression; however, in terminally 
differentiated cells such as neurons, E2F could cooperate with p53 to initiate other p53-
mediated cellular processes including apoptosis (Pan et al. 1998). Unfortunately, 
expression of proteins mediating apoptosis such as caspase-8 and -9 was not examined 
to determine the potential link between E2F1 up-regulation and apoptosis during 
infection. In subsequent studies, no difference was detected in E2F target genes 
including proliferating cell nuclear antigen (PCNA) and cyclin A, which are important for 
cell cycle progression, or p19ARF, which mediates p53-dependent apoptosis in neurons 
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(Wang et al. 2010). Thus, the consequences of altered cell cycle proteins including E2F 
and pRB in neurons during HIV-1 infection remain to be fully clarified. 
Additionally, it has been shown that the level of MDM4, a homologue of E3 ligase 
murine double minute 2 (MDM2) that negatively regulates p53 activity, is reduced in the 
brain tissues of HIV-1-infected patients and patients with HAD (Colacurcio et al. 2013). 
This was consistent with up-regulated protein levels of p53 in both HIV-1-infected human 
and SIV-infected macaque brain tissues (Garden et al. 2004; Jayadev et al. 2007; 
Jordan-Sciutto et al. 2002; Jordan-Sciutto et al. 2000). In addition to an elevated p53 
signaling pathway, target genes of p53, including p21 and Bax, were both up-regulated 
in neurons and glial cells in HAD tissues (Jayadev et al. 2007). Although p53 was up-
regulated in both astrocytes and microglia identified with cell type-specific markers, no 
distinction between the two glial cell types was made regarding the expression of its 
target genes. To conclude, the levels of various cell cycle regulators are modulated in 
HIV-1-infected tissues and appear to be associated with the onset of HAND. Specifically, 
the p53-p21 pathway, which typically inhibits cell cycle progression, is elevated in 
various CNS cell types, including microglia, during infection. Although the p53-p21 axis 
is well known for its role in cell cycle regulation, evidence suggests its relevance in other 
cellular pathways in a cell type-dependent manner. In addition to regulating the 
expression of cell cycle inhibitors, p53 was also shown to control macrophage activation 
(Su et al. 2013). In murine models, p53 knock-out abrogates IFNγ-induced microglia 
activation, which suggests that the p53 pathway also promotes activation of microglia 
(Jayadev et al. 2011). Therefore, it is important to consider the effect of elevated p53 on 
microglia activation, in addition to cell cycle progression, during HIV-1 infection. Although, 
the consequential impact of the altered cell cycle machinery remains to be clarified, HIV-
1 infection or bystander effects of HIV-1 infection seem to disrupt the delicate balance of 
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cell survival, cell cycle progression and apoptosis, which could contribute to the 
development of HAND. 
1.6.3 HIV-1 infection affects cellular metabolism in microglia 
 Individuals with chronic HIV-1 infection often display severe metabolic disorders 
including disturbance in protein turnover, insulin resistance and altered amino acid 
metabolism (Gostner et al. 2015; Hommes et al. 1990; Vigouroux et al. 1999). 
Metabolomic screening of CSF from HIV-1-infected patients detected elevated levels of 
metabolites typically associated with mitochondrial dysfunction (succinate) and microglial 
activation (glutamate and arachidonate) in patients with HAND compared to those 
without any neurocognitive impairment (Cassol et al. 2014). Elevated kynurenine 
pathway downstream of tryptophan metabolism has also been shown to be associated 
with neurocognitive impairments during HIV-1 infection (Kandanearatchi and Brew 2012). 
Increased concentrations of kynurenine pathway metabolites such as quinolinic acid and 
heightened activities of the kynurenine-catabolizing enzymes have been detected in 
brain tissues as well as CSF of HIV-1-infected patients and SIV-infected macaques 
(Heyes et al. 1998; Sardar et al. 1995; Valle et al. 2004). Microglia is a major source of 
CNS quinolinic acid, which can induce neurotoxicity as an NMDA receptor agonist. 
Importantly, increased production of quinolinic acid is correlated with microglial activation 
and contributes to neurotoxicity during HAND (Drewes et al. 2015; Guillemin et al. 2005; 
Heyes et al. 2001). Infection of primary human microglia using neurotropic HIV-1 also 
results in the release of quinolinic acid and, in return, quinolinic acid treatment seems to 
promote HIV-1 viral replication and elevated CCR5 expression in microglia (Chao et al. 
2000; Kandanearatchi and Brew 2012). Thus, altered kynurenine metabolism in 
microglia during HIV-1 infection could contribute to HAND development. 
In addition to increased amino acid metabolism, activation of autophagy, which is 
a catabolic process that recycles cellular components in the event of nutrient starvation, 
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is also observed in microglia during HIV-1 infection. In primary human microglia cells, 
HIV-1 infection induces activation of autophagy in a time-dependent manner, and knock-
down of beclin 1, which is required for multiple stages during autophagy, results in 
reduced p24 release as well as reduced secretion of pro-inflammatory cytokines (El-
Hage et al. 2015). This study suggests that autophagy activation is essential for viral 
replication as well as infection-mediated immune activation of microglia cells (El-Hage et 
al. 2015). In a large-scale small interfering RNA screen, various proteins essential for 
regulating autophagy, including autophagy-related factors (Atg)7, Atg8 and Atg16L2, had 
been found to be required for HIV-1 infection (Brass et al. 2008). This had been also 
confirmed in T cell lines with stable knock-down of various Atgs (Eekels et al. 2012). The 
dependency of HIV-1 replication on autophagy was highly unexpected since autophagy 
has always been considered as an effective immune defense mechanism against 
intracellular pathogens, including viruses, by promoting the degradation of viral materials 
(Talloczy et al. 2006). It is important to note, however, that HIV-1 infection activates the 
initiation but inhibits the maturation of autophagy, to simultaneously promote autophagy-
dependent processing of viral materials and inhibit degradation of viral proteins by 
autophagy in macrophage lineage cells (Kyei et al. 2009). Interrupted autophagic 
processes could compromise the turnover of various cellular organelles including the 
mitochondrion. As a result, abnormal autophagic activation is detrimental to 
mitochondrial health, which is also observed during HIV-1 infection (Lee et al. 2012; Miro 
et al. 2004; Miro et al. 2003). In fact, abnormal mitochondrial fusion and fission, which 
are critical processes for maintaining overall mitochondrial dynamics, have been 
observed in the brains of patients with HAD compared to HIV-1-infected but 
neurocognitively normal subjects (Fields et al. 2016b). Specifically, the protein levels of 
dynamin 1-like protein, which is a GTPase that promotes mitochondrial fission, are 
reduced in the frontal cortex tissue of patients with HAD (Fields et al. 2016b). 
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Accelerated mitochondria turnover by activating autophagy was sufficient to reverse 
microglial activation in a preclinical, transgenic murine model of HAND (Fields et al. 
2013; Fields et al. 2016a). Taken together, these results suggest a role for altered 
mitochondrial homeostasis in microglial dysfunction during HAND. 
Interestingly, the altered metabolomic profile, inefficient autophagy activation and 
reduced mitochondrial turnover observed in the CNS during HIV-1 infection are 
comparable to what may occur during the aging process, which suggests that altered 
cellular metabolism in microglia may underlie accelerated aging in HIV-1 infected 
patients with neurocognitive impairment (Cassol et al. 2014; Torok et al. 2016)(Table 1). 
1.6.4 Microglia processing of Aβ  protein during HAND 
Clearance of Aβ protein constitutes an essential function of microglia cells. 
Amyloid protein can undergo either the non-amyloidogenic or amyloidogenic pathways. 
In the amyloidogenic pathway, amyloid precursor protein (APP) is enzymatically 
processed to produce Aβ42 or Aβ40, which can then form oligomers and insoluble fibrils. 
Elevated Aβ fibril deposition in brain tissues and correlatively reduced CSF soluble Aβ42 
levels have been described as hallmarks of some neurodegenerative diseases including 
AD (Aguzzi and O'Connor 2010). Intracellular Aβ accumulation has also been linked to 
neuronal damage during aging and development of AD (Baker-Nigh et al. 2015). 
However, clinical studies on amyloid homeostasis during HAND development are not as 
clear-cut. While some groups have described reduced CSF level of Aβ42 comparable to 
that of patients with AD (Brew et al. 2005; Krut et al. 2013), others have found no 
significant differences (Ances et al. 2010; Ances and Ellis 2007). Studies that report 
significantly reduced CSF Aβ42  levels examined subjects with HAD, whereas those that 
do not report reduction enrolled patients with HAND encompassing all stages, including 
the mildest form. It is possible that CSF Aβ42 reduction is only detectable in the latest 
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stages of HAND. All studies on CSF Aβ42 examined patients with mean ages of less than 
50 yrs old, and it is unclear whether an older demographic would yield different results. 
Furthermore, MRI studies do not detect elevated Aβ42 fibrils in patients with HAND 
compared to cognitively normal HIV+ or HIV- controls, and no difference was detected 
between cognitively normal HIV+ and HIV- subjects across all age groups (between 35 
and 65 years of age), which suggest that Aβ42 fibril formation is not altered due to HIV-1 
infection and is not associated with HAND development (Ances et al. 2012; Ortega and 
Ances 2014). Our understanding of amyloid metabolism during HIV-1 infection is further 
clouded by conflicting reports on the association between HAND development and 
Apolipoprotein E (ApoE) expression, which is a significant risk factor for abnormal 
amyloid deposition resulting in sporadic AD development (Kim et al. 2009; Morris et al. 
2010). While some early reports demonstrate increased frequencies of HAD 
development in ApoE carriers, more recent studies do not find a correlation between 
ApoE phenotype and HAND development characterized by either neurocognitive 
impairments or detrimental neuroimaging outcomes (Burt et al. 2008; Cooley et al. 2016; 
Corder et al. 1998; Morgan et al. 2013; Valcour et al. 2004b). These differential results 
could be due to disparities in stages of neurocognitive impairments examined (HAD vs. 
milder forms of HAND) or in ages of study subjects since ApoE was shown to be an 
independent risk factor for HAD in HIV-infected patients who are 50 year of age and 
older but not in younger subjects (Valcour et al. 2004a). ApoE status does not modify 
amyloid deposition during HAND in a cohort largely composed of patients younger than 
50 years old (Ances et al. 2012). The distribution of amyloid protein in the CNS of HAND 
patients has also been examined through immunofluorescence staining of human brain 
tissues. Using antibodies targeting APP/Aβ, both intraneuronal and extracellular diffuse 
APP/Aβ accumulation has been detected in the brains of HIV-1-infected patients (Green 
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et al. 2005; Nebuloni et al. 2001). HAND patients do not display the typical plaques of Aβ 
fibrils observed in AD patients. However, the increased intracellular as well as 
extracellular diffuse Aβ accumulation detected in HAND patients suggests an increased 
pool of soluble Aβs, which could be associated with the presence of dysfunctional 
microglia.  
1.7 The Effect of Viral Proteins on Microglial Function  
 In addition to their susceptibility to infection by HIV-1, microglia in vivo are also 
exposed to several viral proteins such as Tat, gp120, Vpr and Nef, which are released 
by infected cells and can be detected in the CNS (Chang et al. 2011; Mukerjee et al. 
2011). Various studies suggest that exposure to those viral proteins may also result in 
altered microglial function and that these effects could underlie the microglial dysfunction 
observed both in vivo and in in vitro models of infection.   
 Tat is the trans-activating protein of HIV-1 that plays a vital role in HIV-1 viral 
transcription and has been shown to affect multiple cellular functions, thereby 
contributing to the pathogenesis of HIV-1 infection (Romani et al. 2010). An in vitro study 
exposing microglial cells to increasing concentrations of Tat demonstrated a dose-
dependent stimulation of the secretion of cytokines and chemokines (Sheng et al. 2000). 
When exposing microglia to Tat in the presence of specific inhibitors of various signaling 
pathways, it was demonstrated that Tat stimulates the secretion of MCP-1 and 
macrophage inflammatory protein (MIP)-1β by activating extracellular-signal-regulated 
kinases (ERK)1/2 MAPK; IFNγ-induced protein (IP)-10 through phosphatidylinositide 3-
kinase (PI3K) activation; and IL-8 through p38 MAPK activation (D'Aversa et al. 2004). 
Tat also stimulates the production of MCP-1, IL-1β, TNFα and inducible nitric oxide 
synthase (iNOS) in a cyclooxygenase (Cox)-2-dependent manner, downstream of NF-κB 
activation (Flora et al. 2006). Finally, activation of nicotinamide adenine dinucleotide 
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phosphate (NADPH) oxidases also promotes the secretion of various pro-inflammatory 
cytokines and associated neurotoxicity following Tat exposure (Bokhari et al. 2009; 
Jadhav et al. 2014; Turchan-Cholewo et al. 2009).  
 In addition to pro-inflammatory cytokines, Tat activation of p38, p42/44 MAPK 
and NADPH oxidase pathways leads to increased glutamate release, which could 
potentially induce excitotoxicity and further contribute to neurotoxicity (Gupta et al. 
2010). Tat exposure also promotes microglial migration towards, and phagocytosis of, 
axonal arbor, resulting in loss of neuronal synapses (Eugenin et al. 2005; Marker et al. 
2012). 
 The surface gp120 sub-unit of the viral envelope glycoprotein is non-covalently 
bound to the transmembrane sub-unit gp41, and is known to shed in CD4-dependent 
and –independent manners from viral envelope glycoprotein trimers present both in the 
surface of virions and in the plasma membrane of infected cells (Ruprecht et al. 2011; 
Selhorst et al. 2013). This soluble gp120 can engage receptors in multiple cells and 
could thus result in activation of microglia through diverse mechanisms. Exposure to 
gp120 results in up-regulation of intercellular adhesion molecule (ICAM)-1 expression in 
a human astroglioma cell line and primary rat microglia, mediated by protein kinase C 
and tyrosine kinase (Shrikant et al. 1996). Exposure of microglia to gp120 also induces 
an outward K+ current and a concomitant increase in voltage-gated K(v) channel 
proteins, which could lead to elevated cytokine secretion, and subsequently contribute to 
neuronal damage that can be attenuated with K(v) channel blockers (Xu et al. 2011). In 
rat microglia, it was further shown that gp120 enhancement of voltage-gated K(v) 
channels depends on the activation of p38 MAPK pathway (Liu et al. 2012). Exposure of 
microglial cells to gp120 has also been recently shown to induce inflammasome 
activation and associated IL-1β secretion (Walsh et al. 2014). 
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  Although these in vitro studies reveal important information on the effects of viral 
proteins on cellular functions, and specifically in microglia, their physiological relevance 
in vivo needs to be critically assessed, especially with regard to the concentrations of 
viral proteins used in vitro. In in vitro studies, concentrations of Tat in the range of 100 to 
1000 ng/ml are routinely used; this is much higher than the concentrations of Tat 
detected in sera of HIV-1-infected patients, which usually ranges from 1 to 40 ng/ml 
depending on the study (Westendorp et al. 1995; Xiao et al. 2000). It is also possible 
that Tat release from infected cells may lead to locally higher concentrations, but these 
have not been demonstrated to date. Similar criticisms can be made for the studies 
utilizing gp120 proteins. While earlier studies may have detected higher serum 
concentrations of the envelope glycoprotein gp120 (Gilbert et al. 1991; Oh et al. 1992), 
more recent studies reported lower levels in the plasma of HIV-1-infected patients in the 
range of 0.5-15.6 ng/ml (Rychert et al. 2010), and even undetectable amounts in serum 
samples from patients with low-to-undetectable viremia (Santosuosso et al. 2009). It has 
also been shown in high viral load, rhesus macaques acutely-infected with a simian-HIV 
(or SHIV, encoding the HIV-1 envelope glycoproteins in an SIV genome) that HIV-1 
gp120 was present in a much higher concentration in lymph node lysates than in plasma 
(218 ng/ml vs. 1.5 ng/ml, respectively) (Stevceva et al. 2008). However, in another 
study, cell-free tissue extracts from lymph nodes and spleens from patients with low-to-
undetectable viremia showed that gp120 was undetectable or below 9 ng/ml 
(Santosuosso et al. 2009). To our knowledge, no study has quantified gp120 levels in 
brains of HIV-1-infected patients, but because one would expect the number and 
proportion of infected cells in the brain to be lower than in lymph nodes or spleens, it 
seems likely that a lower concentration of gp120 would be found in the brain than in 
those other tissues. However, concentrations of 200-500 ng/ml of gp120 are regularly 
used in in vitro studies, and these seem to be well above what might be expected in the 
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brain. In addition, the vast majority of in vitro studies have used the soluble gp120 of a 
CXCR4-using strain, HIV-1IIIB, while the viruses isolated from brain tissues are almost 
exclusively using the alternative co-receptor for infection, namely CCR5. This is because 
infection of macrophages and microglia is only efficient for a subset of CCR5-using 
viruses, and for a few exceptions among the CXCR4-using strains. Thus, rather than 
focusing on the effects of IIIB gp120 in microglia, more studies should be directed to 
address the effects of macrophage/microglia-tropic, CCR5-using gp120 proteins from 
brain- or CSF-derived isolates.  
 Any effects of viral proteins on HIV-1 disease progression in patients likely occur 
through chronic exposure at physiologically relevant concentrations, which are 
conditions that cannot be appropriately modeled with in vitro cell culture systems that 
most often use higher concentrations over acute time courses. To complement results 
obtained using in vitro models, in vivo animal models treated with or expressing viral 
proteins for longer periods of time at lower concentrations have been used to study the 
effects of viral protein exposure during chronic HIV-1 infection. In a non-infectious HIV-1 
transgenic rat model that expresses 7 of 9 HIV-1 viral proteins including gp120, Tat and 
Nef, microglia activation characterized by elevated Iba-1 expression is detected in 
younger groups and declines with age (Reid et al. 2016). Elevated Iba-1 expression 
post-gp120 exposure is also demonstrated using a well-characterized transgenic mice 
model expressing soluble CXCR4-using HIV-1 LAV gp120, and could be reversed by 
modulating pathways that facilitate mitochondria regeneration (Fields et al. 2013; Fields 
et al. 2016a; Maung et al. 2014; Toggas et al. 1994). In a rat model that has been 
transduced to express HIV-1 NL4-3 gp120, also a CXCR4-utilizing envelope, microglia 
activation peaks at week two and then transitions into the onset of apoptosis as 
indicated by significant TUNEL staining in CD68+ cells at one and three months, which 
can be partially protected with antioxidant treatment (Louboutin et al. 2009; Louboutin et 
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al. 2010), suggesting that activated microglia might eventually undergo apoptosis during 
protracted gp120 exposure, possibly due to prolonged oxidative stress. Results 
generated using these models have limited impact, however, considering that, as 
discussed above, gp120s from CCR5-utilizing viral strains are more relevant for studying 
effects on microglia function during HIV-1 infection, and the concentrations of gp120 
obtained in both models have not been examined. 
Microglia activation is also observed using various in vivo models of Tat 
exposure. For example, microglia activation was detected in mice that were injected with 
Tat in the striatum for 7 days (El-Hage et al. 2006; Puccini et al. 2015), and in the brain 
tissues of a rat model two weeks post-stereotaxical Tat injection in the striatum as well 
(Agrawal et al. 2012). Microglia activation upon Tat exposure has been reversed with 
over-expression of antioxidant enzymes including Cu/Zn superoxide dismutase (SOD1) 
and glutathione peroxidase (GPx1), suggesting a role of oxidative stress in Tat-induced 
microglia activation (Louboutin et al. 2014; Louboutin and Strayer 2014). An important 
caveat of the Tat injection models in mice and rats is that the initial injected 
concentrations of Tat are usually much higher than the physiological levels, although the 
actual final concentrations of Tat in the animal brains could be significantly lower due to 
distribution to wider areas as well as Tat degradation in cells and tissues over time 
(Passiatore et al. 2009). Another limitation of the stereotaxical injection models is the 
localized effects around the injection site, which has been the striatum in all studies. 
While the striatum is a brain area with high rate of productive HIV-1 viral replication, 
other areas such as the frontal gyrus are also affected during HAND development and 
should be examined during Tat exposure (Glass et al. 1995). Compared to direct 
stereotaxical injection of Tat in animal brains, a more physiologically-relevant model 
appears to be the conditional Tat transgenic mouse model that could be induced to 
express Tat in astroglial cells at 0.01-0.85 ng/ml. Three months of Tat expression in this 
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model also results in elevated microglia activation evidenced by nitrosative cellular 
stress (Hahn et al. 2015; Kim et al. 2003). 
In addition to gp120 and Tat, other viral proteins including Nef and Vpr have also 
been shown to stimulate production of pro-inflammatory cytokines in microglia as a 
result of oxidative stress (Si et al. 2002; Vilhardt et al. 2002). Overall, HIV-1 viral proteins 
affect multiple functions of microglia including activation, migration, phagocytosis and 
glutamate secretion, all of which are relevant aspects of microglia dysfunction during 
HIV-1 infection and could contribute to the development of HAND. While directly 
exposing microglia in vitro to viral proteins does not necessarily recapitulate all biological 
processes during HIV-1 infection, this approach does afford us the opportunity to dissect 
mechanisms underlying functional changes of both infected and uninfected microglia. 
This type of studies has revealed that many of the phenotypes observed during HIV-1 
infection could be due to activation of various cellular processes that mitigate oxidative 
stress responses, including inflammasome, p38, p42/44 MAPK, NADPH oxidase and 
NF-κB signaling, many of which are known to facilitate cellular senescence (Freund et 
al. 2010) and could be the pathways upon which HIV-1 infection and activation of cellular 
senescence might converge.  
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Table 1. Altered Microglial Functions During HIV-1 Infection 
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1.8 Concluding Remarks 
 With the aging of the HIV-1-infected population in the cART era, health care 
professionals working with HIV-1-infected patients are faced with new challenges of 
treating both aging-associated loss of functions and health risks, as well as the chronic 
viral infection and inflammation associated with it. In addition, it seems well established 
now that the latter seem to have an effect on the former. Although a large recent study 
suggested that HIV-1 infection may cause accentuated but not accelerated aging (Althoff 
et al. 2015), many others have presented evidence of accelerated aging in chronically 
HIV-1-infected populations (Angelovich et al. 2015; Cassol et al. 2014; Chou et al. 2013; 
Gianesin et al. 2016; Horvath and Levine 2015; Levine et al. 2015; Martin et al. 2013; 
Pathai et al. 2014; Pathai et al. 2013a; Pfefferbaum et al. 2014; Schrack et al. 2015), 
involving multiple immune system- and CNS-related functional deficits. This review 
highlighted the many commonalities between functional changes of microglia during 
HIV-1 infection and during aging, including cellular activation, arrested cell cycle 
progression and altered cellular metabolism. Although microglia exhibit various signs of 
activation including secretion of elevated levels of pro-inflammatory cytokines, we do not 
think that activation captures the complexity of altered microglia function during chronic 
HIV-1 infection, especially given the interplay between HIV-1 infection and aging. It is 
also known that some pro-inflammatory cytokines are part of the unique secretory 
phenotype of cellular senescence, a cellular process not only known to occur during 
aging, but that can be at the origin of tissue/organismal aging. Moreover, microglia also 
express higher protein levels of cell cycle inhibitors and exhibit altered autophagy, both 
of which are integral parts of cellular senescence (Table 1), but not of activation. Thus, 
we propose that, although microglia senescence has not been fully characterized, it is 
likely an important part of the processes triggered in the CNS during chronic HIV-1 
infection. Examining pathways implicated in the induction and consequences of cellular 
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senescence during HIV-1 infection could potentially lead to novel therapeutics for the 
treatment of HIV-1-associated end organ diseases, including HAND. 
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Chapter 2: Age-like phenotype in Microglia During HIV-1 Infection 
 
This chapter is submitted as a paper for publication.  
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2.1 Introduction: 
 Although dementia associated with chronic HIV-1 infection has gradually become 
a rare clinical occurrence in the post combined antiretroviral treatment (cART) era, 
around half of all infected patients continue to develop HIV Associated Neurocognitive 
Disorders (HAND) to varying degrees (Chan and Brew 2014; Heaton et al. 2011; Sacktor 
et al. 2016). Alarmingly, the severity of HAND is expected to rise due to the aging of the 
HIV positive population. Studies show that even the mildest form of HAND—
asymptomatic neurocognitive impairments (ANI) – could potentiate age-associated 
cognitive impairment resulting in the development of more serious neurocognitive 
deficits later in life as the patients age (Grant et al. 2014). Currently there are no therapy 
designed specifically for the treatment of HAND and more studies are needed to reveal 
mechanistic insights for the design and development of targeted, protective and 
adjunctive therapies that could more effectively ameliorate the neurocognitive 
impairments during chronic HIV-1 infection.   
 Microglia cells constitute a major target of productive HIV-1 infection in the CNS 
and could potentially serve as the cellular reservoir during chronic HIV-1 infection 
refractory to cART (Gonzalez-Scarano and Martin-Garcia 2005). A plethora of studies 
have demonstrated that microglia become activated during HIV-1 infection as evidenced 
by up-regulation of activation markers including HLA DR and release of pro-inflammatory 
cytokines such as TNFα, owing to both active viral replication and exposure to viral 
proteins (Flora et al. 2006; Garvey et al. 2013; Tatro et al. 2014; Walsh et al. 2014). It 
has been proposed that functional changes of microglia, particularly microglia activation 
during HIV-1 infection, might contribute to the development of HAND(Garvey et al. 2013). 
Furthermore, it is also known that microglia undergo aging associated functional 
changes and activation could be a component of the microglia aging program in both 
healthy subjects as well as patient with aging associated neurocognitive impairments 
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(Frank et al. 2006; Schuitemaker et al. 2012; Wong 2013). It was suggested that the 
activation of microglia could be an essential component of microglia function to maintain 
CNS homeostasis, however, persistent and unregulated microglia activation could result 
in dysfunctionally aged microglia with characteristics resembling cells that undergo 
senescence (Flanary and Streit 2004; Streit et al. 2004). Cellular senescence is known 
to be associated with loss of organ function associated with aging including the onset of 
Alzheimer’s disease (Bhat et al. 2012).  Evidence suggests that microglia could develop 
an age-like phenotype that resembles cellular senescence during the development of 
HAND. For instance, studies demonstrate elevated p53-p21 pathway, which is a 
characteristic marker of cellular senescence, in brain tissues of diseased HIV positive 
patients who developed HAND compared to neurocognitively normal patients (Garden et 
al. 2004; Jayadev et al. 2007).  
 To explore whether microglia undergo age-like process during HIV-1 infection, 
we examined various markers of aging associated cellular senescence including cell 
cycle inhibitors (p21, p53 and p16), DNA damage associated p53 binding protein 1 
(53BP1) foci formation, senescence associated β-galactosidase (SA-β-gal) activity, and 
the development of Senescence Associated Secretory Phenotype (SASP) (Munoz-Espin 
and Serrano 2014). Additionally, since recent publications indicate that mitochondrial 
dysfunction is a crucial component of organismal aging, either as a cause or 
consequence to the onset of the aging process, we examined the production of 
mitochondrial reactive oxygen species (ROS) and mitochondrial electron transport chain 
(ETC) respiration (Wiley et al. 2016).   
Our results indicate that HIV-1 infection could lead to the development of age-like 
phenotypes in human fetal microglia including elevated p21 expression, formation of 
53BP1 foci, elevated SA-β-gal activity and the development of SASP. Associated with 
the onset of age-like phenotypes, we also detected elevated mitochondrial ROS 
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production as well as reduced basal ETC respiration, maximal ETC respiration and ATP-
linked ETC respiration. Interestingly, we also observed that supernatant from age-like 
microglia induced elevated aging associated markers in naïve microglia cells, suggesting 
that components of SASP could initiate age-like program in microglia, which could 
amplify the detrimental effects of aging microglia during HIV-1 infection. 
2.2 Materials and Methods    
 
2.2.1 Cell Culture  
 Human fetal microglia (HFM) cells derived from fetal brain tissue (gestational age, 
16-18 weeks) were provided by Temple Comprehensive NeuroAIDS Center Basic 
Science Core-1 in full compliance with National Institutes of Health and Temple 
University ethical guidelines. Cells are cultured at 37°C and 5% CO2 in Microglia Growth 
Media (DMEM:F12, 15% FBS , 2 mM L-glutamine, 50mg/L Gentamicin, 5ug/mL 
Fungizone, 10mg/L Insulin, 10ug/L D-biotin, 10 mL NI supplement).  
2.2.2 Flow Cytometry Analysis  
 HFM purified by shaking contain >96% Ionized Calcium Binding Adaptor 
Molecule 1 (Iba-1)-positive cells (Figure 2). Positivity of Ionized calcium-binding protein 1 
(Iba1) and cell cycle profile of microglia cells were determined by FACSCaliburTM (BD 
Biosciences, San Jose, CA). To analyze Iba-1 level, cells were fixed and permeabilized 
and then incubated with FITC conjugated anti-Iba-1 antibody (Abcam ab 15691; clone: 
1022-5; Isotype: IgG2b) at 2.5ul/106 cells or isotype control antibody at 2.5ul/106 cells for 
30 min on ice. To analyze cell cycle, cells were harvested and fixed with cold absolute 
ethanol while vortexing followed by 1 hr incubation at 4°C. Post fixation, cells were 
incubated with 1 ml propidium iodide (PI) (Sigma, St. Louis, MO) staining solution 
containing 10ug/ml RNase A (Worthington Biochemicals, Lakewood, NJ) (Figure 3). The 
results were then analyzed with FlowJo. Mitochondrial ROS Analysis: For mitochondrial 
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ROS studies, cells were incubated with 5  µM MitoSox superoxide anion indicator 
(Molecular Probes, Carlsbad, CA) in microglia medium at 37°C in 5% CO2 for 30  min, 
harvested in 2.5% trypsin–EDTA, re-suspended in 200  µL of complete growth medium, 
and analyzed immediately with a Guava Easy-Cyte Mini using the Guava Express Plus 
program (Millipore, Billerica, MA). Data is then analyzed using InCyteTM (Millipore, 
Billerica, MA) and mean fluorescence intensity is obtained for comparative analysis 
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Figure 2. HFM is Positive for Iba-1 Staining. HFM is stained with 
macrophage/microglia marker Iba-1. Histogram is shown to the right. Red line 
represents isotype control for Iba-1 and blue line represents Iba-1 staining.  
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Figure 3. Cell Cycle Profile. HFM and 293T cells were fixed with ethanol, stained with 
PI and analyzed for DNA content. A. 89.8% of HFM were in G1/G0 phase, 9.67% of 
HFM were in S phase and 1.73 e-3 % HFM were in G2 phase. B. 34% of 293T cells were 
in G1/G0 phase, 58.3% of 293T were in S phase and 9.96 % 293T were in G2 phase. 
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2.2.3 Viral Production and Infection  
 To produce Env-pseudotyped, luciferase-reporter viruses, 293T cells were co-
transfected using calcium phosphate precipitation (ProFection Mammalian Transfection 
System, Promega, Madison, WI) with VSV-G expression vector and with the Env-
deficient, pNL4-3-luc+env- provirus. pNL4-3-luc+env-  was developed by N. Landau by 
introducing a frame shift mutation in the env gene of pNL4-3-luc+ vector. VSV-G 
expression vector is utilized to facilitate cellular entry. For controls, 293T cells were 
transfected with either VSV-G or pNL4-3-luc+env- expression vectors alone. Culture 
supernatants containing the pseudotyped particles or control proteins were collected 48–
72 hours after transfection, clarified by centrifugation, aliquoted and stored at -80°C until 
use. 1:2 dilution of viral stocks were used to infect target cells (HFM) at 37°C and 5% 
CO2. To assess infectivity, at 6 days post-infection, infected cells were washed with PBS 
and lysed, and infectivity was measured by detecting luciferase activity (Luciferase 
Assay System, Promega) in a microplate luminometer (GloMax, Promega) (Figure 4). 
Multiplicity of infection (MOI) of 0.005 was used. MOI was assessed based on TCID50 
values. TCID50 assays were conducted in HFM plated at 2*10^4 cells per well in a 96-
well plate. Twelve 1:2 serial dilutions of viral stocks were performed in quadruplicates 
per dilution. Luciferase activities were used to determine TCID50/mL using the Spearman 
and Kärber algorithm(Ramakrishnan 2016). MOI was then calculated using the following 
equation: 𝑀𝑂𝐼   = (!.!  !  !"#$!"  !  !"#$%&  !"  !"#$%&!'"  )!"#$%  !"#$%&  !"  !"#$%!  !"##$  .  
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Figure 4. Flow-chart of Experimental Design.   
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2.2.4 Senescence-associated β-galactosidase activity 
 Senescence-associated beta-galactosidase (SA β-gal) activity was performed as 
previously described(Bitto et al. 2010). Briefly, following exposure to HIV-1 or 
transfection control supernatant, microglia were fixed in 2% formaldehyde/0.2% 
glutaraldehyde for 5 minutes and stained overnight for SA β-gal activity using X-gal as 
substrate. The percent of positive (blue) cells were counted. At least 200 cells were 
counted per condition, in triplicate.  
2.2.5 Immunoblotting 
 Primary human fetal microglia were incubated with HIV-1 or control supernatant 
diluted in microglia media. After 4 days, media was changed. Cell lysate was collected 8 
days post-treatment in RIPA buffer containing protease and phosphatase inhibitors. 
Western blot analysis was performed under standard conditions using 20 µg of total cell 
proteins and stained for specific proteins using anti-p16INK4a (1:200, BP Pharmingen, San 
Jose, CA), anti-p21(1:200, H-164, Santa Cruz Biotechnology), anti-p53 (1:500, Ab-6, 
Calbiochem, Billerica, MA) antibodies as well as anti-β-actin (1:500, Sigma Aldrich; St. 
Louis, MO) or anti-GAPDH  (1:500, Calbiochem, Billerica, MA)) antibodies as loading 
controls.  
2.2.6 Immunofluorescence  
 Cells were plated in Falcon Culture Slides (Corning) at 104 cells per chamber 
post treatment. Cells were first fixed for 10 minutes with 4% paraformaldehyde at room 
temperature (RT) and then permeabilized for 15 minutes with 0.2% TritonX-100. Slides 
were blocked in 5% normal goat serum, 0.1% PBS-BSA for 2 hours, then incubated 
overnight in a humidified chamber at 4ºC with primary rabbit antibody anti- 53BP1(Novus 
Biologicals, Littleton, Colorado) diluted at 1: 500 in PBS 0.1% BSA. Slides were washed 
3 times for 5 minutes in 0.1% BSA and 0.1% Triton X-100, then incubated for 1 hour in 
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the dark at room temperature with the secondary antibody goat anti-rabbit Alexa Fluor 
555 (Invitrogen; Carlsbad, CA). After 3×5 minute washes in 1X PBS with 0.1% BSA and 
0.1% Triton X-100, slides were incubated with DAPI, and mounted with Vectashield 
Mounting Medium (Vector Laboratories, Inc.; Burlingame, CA). Cells were visualized 
using an Olympus BX61 fluorescence microscope coupled with a Hamamatsu ORCA-
ER camera and using Slide Book 4 software version 4.0.1.44 (Intelligent Innovations, 
Inc.; Denver, CO).  
2.2.7 Mitochondrial Electron Transport Chain (ETC) Function 
 For real-time analysis of Oxygen Consumption Rate (OCR), microglia were 
analyzed with an XF-96 Extracellular Flux Analyzer (Seahorse Bioscience, North 
Billerica, MA). Three consecutive measurements were obtained under basal conditions 
and after the sequential addition of 5 µM oligomycin, to inhibit mitochondrial ATP 
synthase; 4 µM FCCP (fluoro-carbonyl cyanide phenylhydrazone), a protonophore that 
uncouples ATP synthesis from proton gradient generated the electron-transport chain 
through respiration; and 1.8 µM rotenone plus antimycin A, which inhibit complexes I and 
III respectively of the electron transport chain (Seahorse Bioscience, North Billerica, MA). 
In this assay, basal oxygen consumption can be established as measured of OCR in the 
absence of drugs.  Reduced OCR after the addition of oligomycin and of rotenone and 
antimycin indicate that cells are consuming less oxygen in response to reduced 
mitochondrial oxidative phosphorylation. Maximal OCR occurs after the addition of 
FCCP due to cells’ attempt to maintain a proton gradient across the inner mitochondrial 
membrane by increasing the consumption of oxygen (Huang et al. 2014). The 
oligomycin sensitive portion of mitochondrial respiration represents ATP-linked OCR and 
oligomycin insensitive portion represents proton leak (Keuper et al 2014) (Figure 5). The 
OCR is represented as absolute values (pMoles/min) normalized by the number of cel 
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Figure 5. Mitochondrial Respiration Analysis. Parameters of mitochondrial functions 
include basal respiration, ATP linked respiration, maximal respiration and spare 
respiration can be calculated based on oxygen consumption rates upon treatments with 
oligomycin, FCCP and Antimycin A & Rotenone.  
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2.2.8 Analysis of Cytokines Secreted by Human Microglia Cells  
 Control and infected HFM were washed twice with PBS and supernatant was 
replaced with serum-free MCDB105 media 4 days post treatment (Sigma Aldrich; St. 
Louis, MO). After 24-hour incubation, conditioned media were collected and cells were 
trypsinized and counted to determine cell number for normalization. Human cytokine 
antibody array (RayBiotech, Inc.; Norcross, GA) was used to detect cytokines present in 
the collected media according to product manual. The intensity of the signal on the array 
membranes was quantified by densitometry using ImageJ (NIH; Bethesda, Maryland) 
and then normalized by cell number. Supernatant from three cases were analyzed to 
confirm the secretory profile. To validate selected cytokines that are altered in all three 
cases, enzyme-linked immunosorbent assay (ELISA) for Interleukin 8 (IL8), Interleukin 6 
(IL6), Vascular Endothelial Growth Factor A (VEGF-A) and Granulocyte Macrophage 
Colony-Stimulating Factor (GM-CSF) (eBioscience; San Diego, CA) were performed. 
Results were normalized to the number of cells and represented in ng/ml per 106 cells.   
2.2.9 Supernatant Transfer Assay  
 To examine whether components of the microglia supernatant post infection 
affect innocent bystander cells, supernatant transfer assays were performed. Specifically, 
supernatant from infected, infected and control cells were collected four days post 
infection. treatment naïve microglia cells were incubated with supernatant diluted with 
microglia media at 1:3. One day post treatment, cell lysates were collected and 
examined for protein expressions of p21 and rabbit anti caveolin-1 (1:300, Cell Signaling; 
Danvers, MA).    
2.2.10 Nucleoside (dNTPs) Treatment of Cells   
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 Cell were treated with 250 nM of nucleoside cocktails (gift from Dr. Rugang 
Zhang, Wistar Institute Philadelphia, PA) at the same time as infection and replenished 
every four days.   
 
2.2.11 Viability Staining  
 Cells were trypsinized and 4*10^4 cells were stained with ViaCount Reagent 
(Millipore, Billerica, MA) and analyzed with Guava ViaCount software (Millipore, Billerica, 
MA) Percentage of nucleated and viable cells were graphed. Heat killed cells were used 
as positive control.   
 
2.2.12 Statistical Analysis  
 Nonparametric analyses Paired Wilcoxon Signed Ranks Test (2-tailed) were 
performed with SPSS (IBM, NY).  p values that indicate statistical significance or trends 
approaching significance are annotated on the graphs. All p values are presented in 
Appendix A.    
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2.3 Results:   
 
2.3.1 Development of Age-like Phenotype in Microglia During HIV-1 Infectio 
 To determine whether microglia develop senescent phenotypes during HIV-1 
infection, we examined various senescence markers including β-gal activity, expression 
of cell cycle regulators including p21, p53 and p16 as well as 53BP1 foci formation. 
Primary human fetal microglia were incubated with VSVg pseudotyped HIV-1pNL43, fresh 
media and transfection control containing VSVg or pNL43 for 8 days. Luciferase 
activities were measured to confirm infection (Fig. 27). Cell cultures incubated with 
VSVg-pNL43 infectious virions have luciferase light units around 100000 in log scale 
compared to cells incubated with control supernatants (uninfected, VSVg and pNL43 ) 
with luciferase light units around 90 in log scale indicating successful infection in VSVg-
pNL43 treated cells but not control treated cells.  
 To assess the development of SA β-gal, additional cells were stained for β-gal 
activity and images were taken and analyzed using ImageJ as well as CellProfiler 
(Figure 6). Numbers of cells positive for β-gal activity as indicated by blue color were 
counted. Samples infected with VSVg pseudotyped HIV-1pNL43  contained significantly 
elevated percentage of positive cells for SA β-gal (25.1%) compared to all controls 
(untreated: 10.3%, VSVg 10.9% and pNL43: 14.6%) (Figure 7). Treatment with 
Neocarzinostatin, a DNA damage agent used as inducer of senescence, results in the 
highest percentages of cells positive for SA β-gal (32.3%) (Hewitt et al. 2012). The 
elevated incidence of SA β-gal positivity post HIV-1 infection suggests that HIV-1 
infection, either the process of viral infection or exposure to soluble factors associated 
with viral infection, results in the development of cellular senescence in microglia cells. 
 To perform a more comprehensive analysis of the senescence program, protein 
expression of cell cycle regulators p16, p53 and p21, were analyzed upon incubation 
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with VSVg pseudotyped HIV-1pNL43 or controls since elevated levels of these markers 
have been observed during the development of cellular senescence in several cell types 
including brain cells (Campisi and d'Adda di Fagagna 2007). Post treatment, lysates 
were extracted to assess the protein level of p53, p16 and p21 using Immunoblot (Figure 
8). Compared to control treated cells, HIV-1 infected microglia exhibit significantly 
elevated p21 expression (3.14 fold increase over untreated controls) compared to VSVg 
treated (1.14 fold increased over untreated controls) (Figure 9). Although infected 
microglia also express higher levels of p21 compared to pNL43 treated controls (0.95 
fold increase over untreated), the difference is not statistically significant. No statistically 
significant change is observed in p53 and p16 levels. This suggests that HIV-1 infection 
induced microglia senescence likely occur through the p21 pathway and not the p16 
mediated signaling pathway. This is further strengthened by the observation of elevated 
53BP1 foci (Figure 10). 53BP1 foci is constitutively detected in untreated cells 
suggesting basal level of on-going DNA damage response to maintain genomic stability 
as a house-keeping function. The prevalence of 53BP1 foci formation is significantly 
elevated in infected cultures. 53BP1 foci formation indicates the activation of DNA 
damage response post infection upstream of p21 pathway (Lossaint et al. 2011). 
Activation of DNA damage repair has been previously reported to be a critical step 
required for efficient HIV-1 infection, which could contributes to the onset of cellular 
senescence since DNA damage response including the formation of 53BP1 foci, is often 
observed in senescent cells (d'Adda di Fagagna et al. 2003; Roshal et al. 2003). Overall, 
elevated SA β-gal activity, increased p21 expression and formation of 53BP1 foci all 
support the development of senescence program in microglia during HIV-1 infection.  
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Figure 6. SA-β-gal Staining of HFM Post HIV-1 Infection. Representative pictures and 
of Senescence Associated β-gal (SA-β-gal) positive cells (blue). Controls and infected 
cells were fixed and stained to detect β-gal activities. More SA-β-gal positive cells are 
detected in VSVg pNL43 and neocarzinostatin treated cells indicating elevated β-gal 
activities compared to all controls.  
Untreated
VSVg VSVg pNL43
NeocarzinostatinpNL43
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Figure 7. Increased percentages of cells positive for Senescence Associated β-gal 
(SA- β-gal) post HIV-1 infection. Total of 8 cases were used. Untreated: n=8, pNL43: 
n=4, VSVg; n=5, VSVg pNL43, n=7 and Neocarzinostatin, n=3. Black bars represent the 
medians for each treatment group (Untreated =10.3; VSVg = 10.9; pNL43 = 14.6; VSVg 
pNL43 = 25.1; Neocarzinostatin = 32.3). Nonparametric analysis (2-tailed) was 
performed. p values are annotated on the graph. * indicates statistical significance.  
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Figure 8. Immunoblot of cell cycle regulators. p53, p21, p16 and GAPDH proteins 
levels were detected with antibodies for untreated, pNL43, VSVg, VSVg pNL43 and 
Neocarzinostatin treated samples. Fold change of densitometry values for each 
treatment over untreated is annotated below the corresponding lanes.  
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Figure 9. Elevated p21 protein expression post HIV-1 Infection. Densitometry values 
normalized by untreated cells for each treatment are graphed. Total of 7 cases were 
analyzed. Untreated: n=7, VSVg: n= 6, pNL4-3: n= 3, VSVg pNL4-3: n=7, 
Neocarzinostatin, n=4. Black bars represent the medians for each treatment group 
(pNL43 = 1.14; VSVg = 0.95; VSVg pNL43 = 2.15). Nonparametric analysis (2-tailed) 
was performed. p values are annotated on the graph. * indicates statistical significance. 
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Figure 10. Increased 53BP1 DNA damage foci formation post HIV-1 infection. 
Immunofluorescence staining for DNA damage foci 53BP1 (red) and nuclei marker DAPI 
(Blue) are shown. 
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2.3.2 Elevated Mitochondrial Reactive Oxygen Species (ROS) Production is 
Associated with Microglial Age-like Phenotype 
     Mitochondrial ROS associated oxidative damage contributes to the development 
of various neurodegenerative diseases and therapies targeting ROS generation in 
mitochondrial holds great promises in protecting neuronal integrity(Lin and Beal 2006). 
Recent reports strongly suggest an association between mitochondrial dysfunction and 
the development of senescence in various cell types. To explore whether mitochondrial 
integrity in microglia during HIV-1 infection is altered in the context of microglial aging, 
we measured mitochondrial ROS production post HIV-1 infection. Primary human fetal 
microglia were infected with HIV-1 and then incubated with MitoSOX, a dye specific for 
mitochondrial ROS (Mukhopadhyay et al. 2007; Nacarelli et al. 2014). HIV-1 infected 
cells demonstrated significantly elevated mean fluorescence intensity (MFI) (median of 
53) post staining compared to untreated cells (median of 26) suggesting elevated 
accumulation of ROS in mitochondria (Figure 11&12). Although infected cells also 
demonstrate higher MFI compared to VSVg (median of 38) and pNL43 (median of 47.8) 
control treated cells, the differences are not statistically significant, suggesting that 
increased mitochondrial ROS is not specific the HIV-1 infection process but a general 
stress response to external stimuli.  
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Figure 11. Flow-cytometry analysis of Mitochondrial ROS. Flow-cytometry was used 
to analyze MitoSOX staining intensity. A. Scatter plot of microglia demonstrating gating 
strategy. B. Histograms of fluorescence intensity for MitoSOX in control and infected 
samples. Dotted (unstained controls) and solid lines (stained samples) are color-coded 
to represent treatment groups as annotated in the legend.  
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Figure 12. Elevated Mitochondrial ROS Production post HIV-1 Infection. Mean 
MitoSOX fluorescence intensity for control and infected cells post staining controlled for 
auto-fluorescence. Total of 6 cases were analyzed. Black bars represent the medians for 
each treatment group (Untreated = 26; VSVg = 38; pNL43 = 47.8; VSVg pNL43 = 53). 
Nonparametric statistic analysis was performed and p values are annotated on the 
graphs. * indicates statistical significance. 
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2.3.3 HIV-1 Infection Alters Mitochondrial Respiration  
 Since majority of mitochondrial ROS is generated by the electron transport chain 
(ETC), elevated mitochondrial ROS suggest an altered ETC homeostasis during HIV-1 
infection. Mitochondrial ETC function was assessed using Seahorse Extracellular Flux 
(XF) Analyzer(Gallardo et al. 2014). Oxygen consumption rates (OCR) were measured 
in real time under basal condition and when challenged with inhibitors of various electron 
transport chain complexes including oligomycin, FCCP, and Antimycine A/Rotenone. 
The OCR of infected microglia was compared to that of control treated microglia (Figure 
13). Basal respiration, ATP-linked respiration, maximal respiration, proton leak, and 
spare respiration were calculated based on OCRs. Figure 13 shows that the non-
mitochondrial associated respiration is reduced to similar levels for infected as well as 
VSVg and pNL43 control treated cells suggesting that supernatant of transfected 293T 
cells inhibits cellular respiration that is not dependent on mitochondria. Basal respiration 
in VSVg-pNL43 infected cells (median of 38.5) is significantly lower than VSVg controls 
(median of 92) and lower than pNL43 controls (median of 99) (Figure 14). ATP-linked 
respiration in VSVg-pNL43 infected cells (median of 11) is also significantly lower than 
untreated (median of 23) and VSVg (median of 15) controls (Figure 15). Maximal 
respiration is significantly lower in VSVg-pNL43 infected cells (median of 59.8) 
compared to VSVg treated control cells (median of 87.7) as well (Figure 16). Proton leak 
and spare respiration were not significantly different between the controls and infected 
HFMs (Figure 17&18). Reduced basal, ATP-linked and maximal respiration in VSVg-
pNL43 treated HFM compared to controls suggest impaired mitochondrial function as 
well as mitochondrial-linked cellular metabolism in HIV-1 infected microglia cells.  
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Figure 13. Mitochondrial ETC Respiration Graphs. Oxygen consumption rate 
normalized by cell number (pMoles/min per 10^5 cells) is graphed as a function of time 
(minutes). First black line indicates addition of 5 µM oligomycin, second black line 
indicates addition of 4 µM FCCP (fluoro-carbonyl cyanide phenylhydrazone), and third 
black like indicates addition of 1.8 µM rotenone plus antimycin. Data points represent 
averages of multiple cases as indicated in the legend.  
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Figure 14. Basal ETC Respiration. Basal respirations are calculated and graphed. 
Medians for basal respirations are: Untreated = 51; VSVg = 92; pNL43 = 99; VSVg 
pNL43 = 38.5. Nonparametric statistic analysis was performed and p values are 
annotated on the graphs.* indicates significance.    
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Figure 15. ATP linked ETC Respiration. ATP linked respirations are calculated and 
graphed. Medians for ATP-linked respirations are: Untreated = 25; VSVg = 23; pNL43 = 
15; VSVg pNL43 = 11.  Nonparametric statistic analysis was performed and p values are 
annotated on the graphs. * indicates significance.    
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Figure 16. Maximal ETC Respiration. Maximal respirations are calculated and 
graphed. Medians for maximal respirations are: Untreated = 69.6; VSVg = 87.7; pNL43 = 
78.1; VSVg pNL43 = 59.8. Nonparametric statistic analysis was performed and p values 
are annotated on the graphs. * indicates significance.    
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Figure 17. Proton-leak of ETC. Maximal respirations are calculated and graphed. 
Medians for proton leak are: Untreated = 26.3; VSVg = 334; pNL43 = 45.2; VSVg pNL43 
= 27.5. Nonparametric statistic analysis was performed.  
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Figure 18. Spare ETC Respiration. Maximal respirations are calculated and graphed. 
Medians for spare respirations are: Untreated = 21.7; VSVg = 17.4; pNL43 = 12.5; VSVg 
pNL43 = 9.8. Nonparametric statistic analysis was performed.  
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2.3.4 Senescence Associated Secretory Phenotype Post Infection 
 Senescent cells develop a unique secretory phenotype mediated by DNA 
damage response, which both serves as a marker of cellular senescence and also plays 
an important role in the propagation of functional changes associated with senescence 
(Rodier et al. 2009). To examine the global cytokine profile secreted by microglia during 
HIV-1 infection, supernatants were analyzed using antibody array membranes (Figure 
19). Thirteen cytokines including IL-6, IL-8, Vascular Endothelial Growth Factor (VEGF)-
A and Granulocyte-macrophage colony-stimulating factor (GM-CSF), which are all 
classically associated with the development of cellular senescence (Coppe et al. 2010), 
were detected at elevated levels in the supernatant post infection compared to 
supernatant from untreated cells  (Figure 20). Some cytokines including IL-6 and IL8 
were present at basal conditions and secreted at much higher levels post infection. 
Selected cytokines such as VEGF-A and GM-CSF were absent in untreated cells but 
secreted at detectable albeit low levels post infection, which could also be 
physiologically significant (Figure 20). To quantitatively confirm the levels of secreted 
cytokines, we measured protein concentrations of secreted IL8, IL-6, VEGF-A and GM-
CSF using ELISAs. In seven cases, IL8 levels were consistently elevated post infection 
(median: 108 pg/ml per 10^6 cells) compared to all controls (Figure 21).  IL6 levels were 
also significantly elevated post infection (median: 470.87 pg/ml per 10^6 cells) compared 
to untreated (median: 64.04 pg/ml per 10^6 cells and pNL43 (median: 284 pg/ml per 10^6 
cells) control cells. The median IL6 level of infected cells was also higher than that of 
VSVg (median: 284.01 pg/ml per 10^6 cells) control cells, approaching significance 
(Figure 22). VEGF-A (Figure 23) and GM-CSF (Figure 24) levels were not significantly 
altered post treatments.  
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Figure 19. Antibody Array Immunoblots for Secreted Cytokines. Cytokine 
secretion profiles of untreated and HIV-1 infected samples demonstrated using antibody 
arrays. Three pairs were analyzed and result of one representative pair is shown. Arrows 
point to the cytokines that are evaluated with ELISAs (IL6, IL8, GM-CSF and VEGF-A). 
Representative images shown were obtained with supernatant from HFM 20.  
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Figure 20. Altered Cytokine Secretion Profile post HIV-1 Infection. Cytokine 
secretions of microglia were examined using antibody array membranes. Fold changes 
of densitometry values from infected microglia normalized by untreated are graphed. 
Thirteen cytokines consistently elevated for three cases are shown. Abbreviations: 
Granulocyte chemotactic protein (GCP)-2; Macrophage migration inhibitory factor (MIF);  
CXC chemokines growth-regulated oncogene (GRO) a/b/g;  TNF Super Family (SF) 
(TNF SF) 14;  Insulin-like growth factor-binding protein (IBP) -1;  Tissue inhibitor of 
metalloproteinase (TIMP)-2.  
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Figure 21. Elevated IL8 Secretion Post Infection. Secreted IL8 proteins in the 
supernatant were measured with ELISA for 7 cases. Medians for IL8 protein 
concentrations are: Untreated = 108; VSVg = 265; pNL43 = 411; VSVg pNL43 = 725. 
Nonparametric statistic analysis was performed and p values are annotated on the 
graphs. * indicates statistical significance. 
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Figure 22. Elevated IL6 Secretion Post Infection. Secreted IL6 proteins in the 
supernatant were measured with ELISA for 7 cases. Medians for IL6 protein 
concentrations are: Untreated = 64.04; VSVg = 271.63; pNL43 = 284.01; VSVg pNL43 = 
470.87. Nonparametric statistic analysis was performed and p values are annotated on 
the graphs. * indicates statistical significance.    
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Figure 23. GM-CSF Secretion Post Infection. Secreted GM-CSF proteins in the 
supernatant were measured with ELISA for 8 cases. Medians for GM-CSF protein 
concentrations are: Untreated = 0; VSVg = 21.0; pNL43 = 23.9; VSVg pNL43 = 46.5. 
Nonparametric statistic analysis was performed.  
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Figure 24. VEGF-A Secretion Post Infection. Secreted VEGF-A proteins in the 
supernatant were measured with ELISA for 8 cases. Medians for VEGF-A protein 
concentrations are: Untreated = 887; VSVg = 535.9; pNL43 = 546; VSVg pNL43 = 1319. 
Nonparametric statistic analysis was performed. 
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2.3.5 Nucleoside Treatments Attenuate Age-like Markers 
 Nucleosides (dNTP) treatments have been previously shown to prevent and 
reverse oncogene induced cellular senescence by restoring genomic stability (Aird et al. 
2013). Since DNA damage response is elicited during HIV-1 infection of microglia, we 
proposed that dNTP treatment could ameliorate aspects of microglia age-like phenotype 
during HIV-1 infection. To test whether dNTPs could effectively prevent microglial age-
like phenotype during infection, HFM were simultaneously incubated with dNTPs and 
VSVg pseudotyped HIV-1pNL43 viral particles. dNTP treatments reversed elevated p21 
expression post HIV infection (Figure 25). Furthermore, dNTP treatments reduced IL8 
secretion associated with HIV-1 infection at 250nM (Figure 26). We further confirmed 
that dNTP treatments did not affect HFM susceptibility to HIV-1 infection thus eliminating 
impaired infection as the mediating mechanism (Figure 27).  These results suggest that 
dNTP could partially reverse selected aspects of HIV-1 infection induced age-like 
phenotype in microglia and could attenuate bystander effects of factors secreted by 
aging microglia.  
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Figure 25. dNTP Treatment Reverses Elevated p21 Protein Levels.  Immunoblot 
demonstrates elevated p21 levels in cells infected with VSVg pNL43 compared to 
controls (Untreated, pNL43, VSVg, and dNTP). Infected cells treated with dNTP (VSVG 
pNL43 dNTP) demonstrated attenuated levels of p21 compared to infected cells. 
Densitometries of p21 are normalized with endogenous control (GAPDH). Fold changes 
of p21 and for various treatment groups over untreated cells are annotated below the 
graphs. 
p21
GAPDH
1.44++++1.52++++3.4+++++4.5++++2.24+++1.18
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Figure 26. dNTP Treatment Reverse Elevated IL8 Secretion. ELISA demonstrates 
elevated IL8 secretion in cells infected with VSVg pNL43 compared to controls 
(Untreated, pNL43, VSVg, and dNTP). Infected cells treated with dNTP (VSVG pNL43 
dNTP) demonstrate slightly attenuated IL8 release compared to infected cells. 
Concentration of IL8 protein is show in pg/ml and normalized per 10^6 cells. Result was 
obtained with HFM20. Since only one donor was used, no statistic analysis was 
performed.   
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Figure 27. HFM Susceptibility to HIV-1 Infection. Control cells, infected cells and 
infected cells treated with dNTP were lysed and assayed for luciferase activities. 
Luciferase light units were graphed in log scale. dNTP treatment does not significantly 
impact HFM infectivity.  
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2.3.6 SASP induced Age-like Markers 
 Molecules secreted by senescent cells could modulate cellular functions of both 
senescent as well as non-senescent cells in the vicinity. It is known that components of 
SASP could both reinforce cellular senescence in cells that are already senescent as 
well as initiate cellular senescence programs in non-senescent cells (Meng et al. 2015). 
As a result, SASP could amplify the effects of senescent cells and contribute to systemic 
effects that are sometimes disproportionally widespread for the low number of senescent 
cells detectable in tissues. To examine whether components of SASP could illicit age-
like responses in uninfected bystander microglia, we examined markers of microglial 
age-like phenotype including p21 and Caveolin-1 in microglia following incubation with 
supernatant from infected and control microglia. In addition to p21, which we have 
shown in Figure 1 to be up-regulated during HIV-1 infection, caveolin-1 protein 
expression was also examined because caveolin-1 has been shown to be elevated in 
various diseases associated with organismal aging and to regulate cellular senescence 
through activation of p53 pathway(Zou et al. 2011). Protein levels of both p21 and 
caveolin-1 were up-regulated in microglia exposed to supernatants from HIV-1 infected 
microglia compared to supernatants from control cells (Figure 28). Elevated levels of p21 
and Caveolin-1 in supernatant transfer assay suggest that molecules secreted by aging 
microglia post HIV-1 infection could initiate the onset of age-like phenotypes in 
neighboring cells. Interestingly, the elevations in p21 and caveolin expression were 
attenuated in cells exposed to supernatant from infected cells that were also treated with 
nucleosides (Figure 28).  
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Figure 28. Supernatant Treatment Results in Elevated Age-like Markers.  
Immunoblot demonstrates elevated p21 and Caveolin-1 levels in cells incubated with 
supernatant from infected cells (VSVg pNL43 Sup) compared to controls (Untreated 
Sup, pNL43 Sup, VSVg Sup, dNTP Sup). Supernatant from infected cells treated with 
dNTP (VSVG pNL43 dNTP Sup) results in attenuated levels of p21 and caveolin-1 
compared to infected cells. Densitometry of p21 and caveolin-1 was normalized with 
endogenous control (GAPDH). Fold changes of p21 and caveolin-1 for various treatment 
groups over cells incubated with supernatant from untreated microglia are annotated 
below the graphs.  
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2.3.7 Viability of HFM Post Treatment 
  Treatments do not significantly affect the viability of HFM. VSVg pNL43 infected 
HFM demonstrate 77% percent viable cells compared to around 88% viability of VSVg 
treated cells and 89% viability of untreated cells (Figure 29). Routine cell culture 
procedures such as trypsinization could have resulted in some cell death, which explains 
why HFM were not 100% viable. Cells treated with HIV-1 (77%) had around 10% lower 
viability compared to the controls (untreated: 89%; VSVg: 88%; pNL43: 84%), which 
suggests that the infection process does results in a low level of cell death. 
Neocarzinostatin treated cells displayed comparable viability (90%) to untreated cells 
showing that the concentration used does not cause cell death. Heat killed sample (half 
of the cells were killed at 100 °C for 10 minutes) only contained 19% viable cells, which 
demonstrates the validity of the assay.  
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Figure 29. Viability Staining.  Treated cells were assayed for viability with Guava 
ViaCount. Nucleated and viable cells appear in the upper left quadrant. Heat-killed 
sample was used as positive control. A&B. Representative graphs of viability staining. C. 
Percentages of viable cells were graphed.   
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Figure 29. Viability Staining Continued.  Treated cells were assayed for viability with 
Guava ViaCount. Nucleated and viable cells appear in the upper left quadrant. Heat-
killed sample was used as positive control. A&B. Representative graphs of viability 
staining. C. Percentages of viable cells were graphed.  
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Figure 29. Viability Staining Continued.  Treated cells were assayed for viability with 
Guava ViaCount. Nucleated and viable cells appear in the upper left quadrant. Heat-
killed sample was used as positive control. A & B. Representative graphs of viability 
staining. C. Percentages of viable cells were graphed.   
 
 
 
 
 
0
20
40
60
80
100
120
Pe
rc
en
ta
ge
/o
f/C
el
ls
/V
ia
bl
e/
(%
)
	  	  
79	  
Chapter 3: Discussion 
 Various studies indicate that HIV-1 positive patients display advanced aging 
compared to their uninfected counterparts as demonstrated by changes in age-
associated parameters including altered DNA methylation (Gross et al. 2016; 
Rickabaugh et al. 2015), reduced telomere stability (Chou et al. 2013; Liu et al. 2015) 
and elevated immune activation (Martin et al. 2013). Cellular senescence could underlie 
this accelerated biological aging. Within a HIV-1 infected cohort that has been previously 
shown to demonstrate advanced aging-associated frailty, premature cellular senescence 
characterized by lower endothelial cell density, was observed in HIV-1 positive patients 
compared to uninfected controls. The lower cell density was correlated with higher 
mRNA levels of cell cycle inhibitor CDKN2A known to mediate cellular 
senescence(Pathai et al. 2013b). Similarly, our results suggest that microglia age-like 
phenotype during HIV-1 infection could be an additional aspect of accentuated and/or 
accelerated aging of HIV-1 positive patients that could potentially contribute to the 
development of HAND during chronic HIV-1 infection (Figure 30).  
 In microglia cells, markers of organismal aging including percentages of cells 
positive for SA β-gal and protein level of p21 are elevated during HIV-1 infection 
suggesting the onset of microglial age-like phenotype (Figure 30). The elevated p21 
protein levels in microglia post HIV-1 infection in vitro is consistent with the increased 
frequency of p21 positive glia cells detected in brain tissues of diseased patients with 
HAD(Jayadev et al. 2007). Elevated p21 during HIV-1 infection has also been previously 
observed in purified primary human CD4+ T cells. It was also shown in the same study 
that elevated p53 upstream of p21 promotes the induction of protein kinase R (PKR) that 
phosphorylates Tat. Phosphorylation of Tat suppresses Tat’s function as HIV-1 
transactivator, which ultimately results in the suppression of HIV-1 viral replication(Yoon 
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et al. 2015). In the present study, elevated level of p21 is observed post infection while 
elevated p53 protein expression is not detected. Since p21 expression is known to be 
regulated by the transcription factor p53, we speculate that p53 is also elevated but 
undetected in our system because it is only transiently increased at an earlier time point 
and is quickly degraded due to its naturally unstable structure (Tsvetkov et al. 2010). 
Given the significant role of p53 in regulating Tat activities, and subsequently HIV-1 viral 
replication, it would be of interest to examine mRNA and protein levels of p53 in future 
studies. It is possible that activation of cellular senescence during HIV-1 infection 
creates a cellular milieu unfavorable for active viral replication through, at least partially, 
inactivation of Tat in microglia cells. This would be of great interest especially 
considering microglia’s potential role as cellular reservoir for HIV-1 in the post cART era. 
If true, cellular senescence could be a potential target for suppressing and ultimately 
eradicating HIV-1 from infected host cells.   Finally, whether p21 regulates microglial 
function remains to be clarified. We could explore how altered p21 protein expression 
modulates microglial function by performing knockdown and/or overexpression 
experiments in untreated and infected cultures.     
 The age-like phenotype post HIV-1 infection is further bolstered by the 
observation of 53BP1 foci formation indicating activation of DNA damage response 
(Figure 30), which could then signal the cell cycle to be arrested by checkpoint proteins 
such as p21 in order to repair aberrant DNA replication. This is the hallmark of cellular 
senescence. Other markers of DNA damage response pathway including ataxia 
telangiectasia mutated (ATM), BRCA1, PCNA and γH2AX should be examined in 
conjunction with 53BP1 to more comprehensively analyze the activation, progression 
and completion of DNA damage repair. Elements of DNA damage response have not 
been extensively characterized in HAND tissues and could be done in future studies.   
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    Mitochondrial dysfunction is closely associated with the development of cellular 
senescence(Salama et al. 2014). Altered mitochondrial mediated energy metabolism 
including reduced ATP synthesis could contribute to the progression of cellular 
senescence (Ziegler et al. 2015). Conversely, cellular senescence could result in 
mitochondrial dysfunction(Passos et al. 2006). We observed elevated mitochondrial 
ROS production as well as reduced mitochondrial respiration linked to ATP production in 
microglia during HIV-1 infection, both of which are aspects of mitochondrial dysfunction 
known to contribute to the development of cellular senescence (Figure 30).  This change 
in mitochondrial function is also consistent with results of clinical studies with HIV-1 
positive patients. Compromised mitochondrial ETC function has been observed in both 
treated and treatment-naïve HIV-1-infected patients (Miro et al. 2004; Miro et al. 2003). 
Moreover, abnormal mitochondrial morphology and mitochondrial dynamics have been 
observed in the brains of patients with HAD compared to HIV-1-infected but 
neurocognitively normal subjects (Fields et al. 2016b). We propose that mitochondrial 
dysfunction in aging microglia during HIV-1 infection may be a component of HAND 
development.  
SASP development is a central aspect of cellular senescence. The most classic 
cytokines of SASP include IL6, IL8 and IL1. In particular, IL1 α has been shown to be an 
indispensable component of SASP regulating IL6/IL8 secretion during cellular 
senescence(McCarthy et al. 2013; Orjalo et al. 2009). As a result, it was perplexing that 
IL1 α was not detected in the supernatant post microglia infection. Recent evidence 
demonstrates, however, that mitochondrial dysfunction induces IL-1 independent-SASP 
profile that is significantly different than SASP induced by DNA damage(Wiley et al. 
2016). Since mitochondrial dysfunction is observed in microglia during HIV-1 infection, 
although unclear whether it is a cause or effect, we stipulate that microglia age-like 
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phenotype during HIV-1 infection could be IL-1 independent considering the potential 
causal role of mitochondrial dysfunction in microglia aging during HIV-1 infection. The 
exact of role of mitochondrial dysfunction in the development of microglial age-like 
phenotype during HIV-1 infection needs to be clarified in future studies. Furthermore, it 
would of interest to distinguish between the effects of DNA damage and mitochondrial 
dysfunction, both of which are observed in microglia during HIV-1 infection, with regard 
to mechanistic pathways underlying SASP development.  
In addition to IL6 and IL8, we also measured GM-CSF and VEGF-A levels with 
ELISAs since GM-CSF and VEGF-A were shown to be up-regulated on the antibody 
membranes. No statistically significant difference was detected between infected 
cultures and cultures exposed to VSVg and pNL43 control supernatants for both GM-
CSF and VEGF-A indicating that the inductions of those two cytokines were not specific 
to infection and not part of the age-like phenotype. In addition to IL8, IL6, GM-CSF and 
VEGF-A, nine other secreted proteins were up-regulated in the infected cultures 
compared to untreated cells including IL7, IP10, GCP-2, MIF, (GRO) a/b/g, TNF SF14, 
IBP -1, TIMP-2 and TGF-3β, all of which play important roles in the regulation of immune 
and/or neuronal functions. There were also other cytokines that were altered in only two 
of the three donors examined and therefore not included in the list. We will selectively 
examine those cytokines with individual ELISAs as well with more donors. For instance, 
GRO a, a member of the GRO a/b/g family, is significantly up-regulated (71 and 155 fold 
increase over untreated) in two donor but not changed in the third donor.  Considering 
the high magnitude of changes observed in two donors and its pertinence to aging 
(Fimmel et al. 2007) as well as neuronal health, we are very interested in confirming 
whether GRO a isoform is elevated in microglia post infection(Gordon et al. 2012).   
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 Incubation with supernatant from infected microglia results in elevated p21 and 
caveolin-1 levels in treatment-naïve microglia (Figure 30). This observation elevates the 
physiological significance of current study since the percentage of infected microglia 
during natural infection could be very low in patients, while the consequence of such 
limited infection could be broad and lasting due to bystander effects as the results 
suggest. Additionally, elevated caveolin-1 levels in cells exposed to SASP could have 
significant ramifications with regards to HIV-1 infection and replication since it is known 
that HIV-1 infection affects caveolin-1 processing and conversely caveolin-1 restricts 
HIV-1 infection(Lin et al. 2015; Lin et al. 2012; van den Berg et al. 2014). Finally, 
caveolin-1 has been shown to modulate various aspects of microglial function including 
amyloid beta phagocytosis, microglia activation and microglial mitochondrial 
respiration(Jang et al. 2015; Niesman et al. 2013). As a result, altered caveolin-1 
expression could have significant effects on various aspects of microglial function 
contributing to HAND development.  
 It is also interesting that nucleosides treatment reverses elevated p21 levels post 
infection as well as p21 and caveolin-1 levels post exposure to supernatant of infected 
cells, suggesting that dNTPs suppresses senescence inducing factor(s) in SASP.  As a 
proof of concept, IL8 levels were reversed in the dNTPs treated cells post infection. 
Since IL8 may not be the factor that is responsible for the induction of p21 and caveolin-
1 in the supernatant transfer assay, future studies are required to determine the specific 
mechanisms underlying SASP-induced elevation in p21 and caveolin-1. In addition, 
further experiments are required to elucidate the mechanisms of action of the 
nucleosides. Nucleosides are used instead of corresponding nucleotides because 
nucleosides can be taken up across the cell membrane through nucleoside transporter 
proteins(King et al. 2006). Considering the dramatic impairment of ATP-linked 
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mitochondrial respiration in microglia during HIV-1 infection, it is possible that impaired 
ATP production contributes to the development of microglia senescence. This should be 
confirmed by measuring the content of dNTPs post infection in future experiments. As a 
result, we propose that the nucleoside adenosine, which is an ATP precursor, might be 
the principle mediator in preventing senescence-like phenotypes. Future studies should 
examine whether adenosine independently prevents the onset of age-like phenotype 
associated with HIV-1 infection in microglia cells. Furthermore, since adenosine is an 
important neurotransmitter regulating various microglial functions including phagocytosis 
and migration through activation of p1 purinergic receptors expressed on the surface of 
human microglia cells (Koizumi et al. 2013), it is important to clarify whether adenosine 
modulates microglial phenotypes through direct activation of purinergic receptors instead 
of contributing to the synthesis of intracellular ATPs.    
 To mechanistically assess whether HIV-1 infection indeed induces the age-like 
phenotypes observed, anti-retroviral treatments targeting various steps of the viral life 
cycle will be utilized to prevent the onset of age-like phenotypes. This intervention will 
help elucidate whether specific steps in viral infection and/or replication facilitate the 
aging process. A potential complication of this intervention is that various studies 
demonstrated anti-retroviral treatments could contribute to the accelerated/accentuated 
aging phenotype in HIV-1 infected population (Payne et al. 2011). As a result, it is 
important that we titrate the compounds to concentrations that would prevent viral 
infection without inducing age-like phenotypes.   
 Another potential mechanism that we are interested in examining is the 
regulation of microglial function by microRNAs (miRNAs). miRNAs are small non-coding 
RNAs that regulate gene expression on the post-translational level. miRNAs have been 
shown to regulate immune activation and cellular senescence, both of which are relevant 
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processes during HIV-1 infection. Selected miRNAs such as miR124 and miR155 have 
been shown to regulate immune activations including those of microglia cells, while 
others have been shown to regulate the onset of cellular senescence including let7 and 
miR146a/b (Benhamed et al. 2012; Bhaumik et al. 2009; Ponomarev 2011; Tarassishin 
et al. 2011). miRNA profiles could be altered during HIV-1 infection, which could then 
subsequently regulate functional changes in microglia including activation and 
senescence. Altered miRNA profile could be a mechanism mediating the onset of age-
like phenotype in microglia during HIV-1 infection.  As a result, we plan to assess how 
HIV-1 infection could affect microglial miRNAs during HIV-1 infection. Many studies have 
detected changes in miRNA profiles in HIV infected patients. Houzet et al demonstrated 
that five highly T cell specific miRNAs are significantly down-regulated including miR150, 
miR191, miR223, miR16 and miR146b in HIV-1 infected patients (Houzet et al. 2008). 
Furthermore, various groups demonstrate that specific miRNA signatures might 
differentiate patients with different patterns of disease progression. It was shown that 
members of miR29, miR125b, 150, and 31 are differentially expressed in HIV elite 
suppressors from viremic patients (Witwer et al. 2012). Swaminathan S et al show that 
let7b and let7f are significantly reduced in infected patients compared to elite 
suppressors (Swaminathan et al. 2012). Study of miRNA profiles of elite suppressors, 
multiple expose uninfected and naïve patients showed that miR155 is the only miRNA 
that could differentiate elite suppressors from native controls(Bignami et al. 2012). 
Disturbance of miRNAs involved in the apoptotic pathway is detected in a group of rapid 
progressors compared to chronic progressors according to a study by Zhang et al 
(Zhang et al. 2013). In addition to the association with overall disease progression during 
HIV-1 infection, specific miRNA signatures is also shown to correlate with the 
development of HAND through analysis of brain tissues, CSF or plasma. Witwar et al 
examined the plasma miRNAs of SIV infected pigtail macaques and demonstrated 
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significant changes in 45 miRNAs. Five of which, including miR146a, correlated with 
severe CNS diseases and additionally, let7e level correlated with IL6 level which is 
associated CNS inflammation(Witwer et al. 2011). Furthermore, 11 miRNAs are 
significantly up regulated in the CSF of patients with HIVE compared to that observed in 
patients without encephalitis (Pacifici et al. 2013). miRNA regulation of CNS integrity in 
the context of HIV-1 infection are cell type specific. In brain sections of SIV infected 
rhesus monkeys, FISH and IF results indicate that miR-142 is up regulated in MAP2+ 
neurons. Elevated miR-142 leads to reduction in SIRT1 expression and consequently 
reduced expression of monoamine oxidase, which could negatively affect 
neurotransmitter production(Chaudhuri et al. 2013). HIV infection could result in elevated 
miR21 in neurons, which could affect potassium current through inhibiting 
MEF2(Yelamanchili et al. 2010). Analysis of frontal lobes of HIVE brain tissues indicates 
down-regulation of miR129-3p and miR130a astrocytes, which contribute to increased 
level of apoptosis mediated by caspase 6 activation (Noorbakhsh et al. 2010). Details 
are presented in Table 1. In vitro studies of cell culture models post HIV-1 infection 
detect changes in miRNA profiles in HIV-1 infected cells compared to controls using 
different cell types including PBMCs, astrocyte, microglia and neurons.  Deep 
sequencing of PBMCs infected with BAL at 27 hours post infection detected significant 
change (>2 fold increase) in only one miRNA-– miR30b-5p(Whisnant et al. 2013). This in 
vitro study contradicts previous reports that detect changes in multiple other miRNAs 
(Chang et al. 2013; Triboulet et al. 2007). This discrepancy could be due to several 
factors: different cells types, (PBMC vs. Jurkat) and different time point post infection. 
Overall, the data suggest that HIV infection could modulate host miRNAs on the cellular 
level. Different miRNA profile is detected in vitro compared to what was observed in 
clinical samples, which suggests that environmental factors other than infection including 
cytokine secretion could modulate host miRNAs. Various studies indicate that distinct 
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miRNAs correlate with disease progression and specifically severity of CNS disorders. 
miRNAs have the potential to be used as biomarkers for HIV/AIDS pathogenesis and 
HAND development. In addition, miRNAs could serve as therapeutic targets. In 
particular, antagomir that targets miR122 has shown clinical promise for the treatment of 
hepatitis C infection(Janssen et al. 2013). Targeting miRNA is a viable approach for 
cancer treatment based on preclinical data(Velu et al. 2013). Additionally, animal models 
are being used to explore whether microRNA antagomirs can be used to treat 
neurological disorders in murine models of ischemic stroke and ALS. Although delivery 
of compounds targeting miRNAs through introcerebroventricular injections is a viable 
option for animal models as described in those publications, alternative approach should 
be fully explored in order to limit treatment complications in patients in a clinical setting 
(Koval et al. 2013; Selvamani et al. 2012). In addition, post treatment analysis of the 
murine models indicates that antagomirs are detectable in multiple cell types of the CNS 
including neurons, astrocytes and microglia cells. miRNA therapy could be explored as a 
potential safe and effective therapeutic approach for treating HAND in the context of 
aging of the population. 
 Since we are working with primary human cells, significant donor-dependent 
variations occur in various phenotypes observed. Some donors would exhibit very strong 
age-like qualities consistently across phenotypes such as HFM 20, which exhibits 
elevated percentages of cells positive for SA- β-gal, elevated p21 levels, elevated IL8, 
reduced basal OCR and reduced ATP linked respiration.  dNTP was shown to prevent 
p21 and IL8 elevation post infection in HFM 20. Other donors, such as HFM 26, only 
exhibit one or two age-like phenotypes post infection. HFM 26 demonstrates increased 
SA- β-gal positivity, but no change in p21 or IL6 levels post infection. It is possible that 
the senescence program is activated to different extend in different donors. It is also 
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important to note that not all phenotypes were examined for every single donor. 
Depending on the number of cells available, selected phenotypes were examined for a 
particular donor. 
 The biggest caveat of the present study is the low statistical significance for 
some experiments due to high variability in results obtained with different cases of 
primary human microglia, which could result from three pitfalls in experimental design 
and execution: 1. variability of microglia from different brain regions; 2. variable infectivity 
of different batches of pseudotype HIV-1; 3. technical inconsistencies. Firstly, recent 
studies demonstrate region-dependent gene expressions of murine microglia, which 
supports the speculation that microglia derived from different brain regions have variable 
functions(Grabert et al. 2016). If different cases of microglia were obtained from different 
brain regions, potential region dependent functional differences could have contributed 
to the variable results we see. Unfortunately, thus far I have not read a paper that 
utilized human microglia from specific regions of the brain for functional studies 
(including gene expression on the protein level) due to the limited amount of cells 
obtained from each tissue preparation. Hopefully, with advancement in primary cell 
extraction from human tissues, we will be able to examine microglia from specific brain 
regions and thus reducing the variability between independent experiments. Secondly, 
pseudotype HIV-1 virus from different preparations can have very different infectivity 
indicated by different luciferase levels, which can contribute to varying percentages of 
cells being infected in a primary microglia culture. Since we hypothesize that HIV-1 
infection is the stressor inducing the aging phenotype in microglia, inconsistent infection 
could lead to variable results. To remediate this source of experimental variability, we 
could scale up to produce enough virus for all experiments in one setting. Lastly, 
although the variability in results could be donor dependent, we have not eliminated 
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technical inconsistencies by repeating experiments with one donor. Given the region 
dependent differences mentioned above, cells from same donor could still present 
intrinsic differences.  
      Although the use of single-round infectious virus provides a clean model to 
examine the effect of HIV-1 infection upon first exposure, the model does not re-
capitulate native infection, in which infectious virions are produced and can infect other 
cells. In future experiments, we will perform follow-up studies utilizing fully infectious 
virus.  
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Figure 30. Working Model. Microglia develop various senescence-like phenotypes 
during HIV-1 infection including elevated SA- β-gal positivity, p21 protein expression and 
formation of 53BP1 DNA damage foci. Altered mitochondrial functions including elevated 
mitochondrial ROS production and impaired ETC respiration are associated with the 
development of senescence like phenotypes. Increased cytokine production 
characteristic of senescence associated secretory phenotype is also detected. 
Components of supernatant post infection leads to the development of senescence 
markers 
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Appendix A  
Tables of p-Values 
 
 
 
 
SA-β-gal  
    
Paired Comparison  VSVg  pNL43  
VSVg 
pNL43 Neocarzinostatin  
Untreated  0.345 0.273 0.018 0.008 
VSVg  
 
1.000 0.080   
pNL43      0.068   
     p21  
    
Paired Comparison  
VSVg 
pNL43 
   VSVg  0.305 
   pNL43  0.046 
   Neocarzinostatin  0.705 
   
     IL8 
    
Paired Comparison  VSVg  pNL43  
VSVg 
pNL43 
 Untreated  0.176 0.075 0.018 
 VSVg  
 
0.249 0.018 
 pNL43      0.028 
 
     IL6  
    
Paired Comparison  VSVg  pNL43  
VSVg 
pNL43 
 Untreated  0.237 0.310 0.018 
 VSVg  
 
0.499 0.063 
 pNL43      0.028 
 
     GM-CSF  
    
Paired Comparison  VSVg  pNL43  
VSVg 
pNL43 
 Untreated  0.046 0.028 0.043 
 VSVg  
 
0.345 0.463 
 pNL43      0.753 
 
     VEGF-A  
    
Paired Comparison  VSVg  pNL43  
VSVg 
pNL43 
 Untreated  0.068 0.068 0.273 
 VSVg  
 
0.715 0.068 
 pNL43      0.068 
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Mitochondrial ROS 
Paired Comparison VSVg pNL43 VSVg pNL43
Untreated 1.000 0.273 0.005
VSVg 0.465 0.068
pNL43 0.273
Basal OCR  
Paired Comparison VSVg pNL43 VSVg pNL43
Untreated 0.068 0.144 0.249
VSVg 0.893 0.043
pNL43 0.080
ATP -linked OCR 
Paired Comparison VSVg pNL43 VSVg pNL43
Untreated 0.465 0.068 0.028
VSVg 0.043 0.043
pNL43 0.080
Maximal OCR 
Paired Comparison VSVg pNL43 VSVg pNL43
Untreated 1.000 0.465 0.116
VSVg 0.225 0.043
pNL43 0.500
Pronton Leak 
Paired Comparison VSVg pNL43 VSVg pNL43
Untreated 0.068 0.465 0.753
VSVg 0.893 0.225
pNL43 0.500
Spare OCR 
Paired Comparison VSVg pNL43 VSVg pNL43
Untreated 0.068 0.068 0.173
VSVg 0.138 0.686
pNL43 0.225
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Appendix B  
List of Abbreviations  
 
 
 
 
Alzheimer’s disease (AD) 
Amyloid precursor protein (APP) 
Apolipoprotein E (ApoE) 
Asymptomatic neurocognitive impairments (ANI) 
Ataxia telangiectasia mutated (ATM) 
Autophagy-related factors (Atg) 
B-cell lymphoma (Bcl)-2 
BCL2 Associated Athanogene (BAG) 3 
BCL2-associated X protein (Bax) 
Beta amyloid (Ab) 
Cerebrospinal fluid (CSF) 
Cu/Zn superoxide dismutase (SOD1) 
CXC chemokines growth-regulated oncogene (GRO) a/b/g  
Cyclooxygenase (Cox)-2 
glutathione peroxidase (GPx1) 
Granulocyte chemotactic protein (GCP)-2;   
HIV Associated Neurocognitive Disorder (HAND) 
HIV-1 encephalitis (HIVE) 
HIV-1-associated dementia (HAD) 
Human Immunodeficiency virus (HIV) 
Human leukocyte antigen-D-related (HLA-DR) 
IFNg-induced protein (IP)-10 
Insulin-like growth factor-binding protein (IBP) -1   
Intercellular adhesion molecule (ICAM)-1 
Interferon (IFN) g 
Interleukin (IL)-4 
Ionized calcium-binding protein-1 (Iba-1) 
Lipopolysaccharide [LPS] 
Macrophage inflammatory protein (MIP)-1b 
Macrophage migration inhibitory factor (MIF)   
Magnetic resonance imaging (MRI) 
Major histocompatibility complex II (MHC II) 
microRNAs (miRNAs) 
Murine double minute 2 (MDM2) 
N-methyl-D-aspartate (NMDA) 
Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases 
Nitric oxide synthase (iNOS) 
Nucleosides (dNTP) 
p53 binding protein 1 (53BP1) 
Positron emission tomography (PET) 
Pre-integration complex (PIC) 
Proliferating cell nuclear antigen (PCNA) 
Reactive oxygen species (ROS) 
Retinoblastoma susceptibility gene product (pRB) 
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Senescence Associated Secretory Phenotype (SASP) 
Senescence Associated β-gal (SA- β-gal) 
Severe combined immunodeficiency (SCID) 
Simian immunodeficiency virus (SIV) 
Tissue inhibitor of metalloproteinase (TIMP)-2. 
TNF Super Family (SF) (TNF SF) 14;   
Toll-like receptors (TLR) 
Transforming growth factor b (TGF-b) 
Tumor necrosis factor (TNF) a 
Vascular Endothelial Growth Factor (VEGF)-A 
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